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GENERAL INTRODUCTION
There are approximately 150 species of Candida out of which only small
numbers are able to establish pathogenesis in humans [1]. Out of the list of all
these species, Candida albicans is the most commonly isolated species
associated with infection. Diseases range from superficial mucosal infections to
systemic mycoses. Under normal conditions, C. albicans exists as a common
member of the oral, gastro-intestinal, and uro-genital microbiota, with carriage
rates ranging from 30-70% among healthy individuals [2, 3]. However, exposure
rates are likely much higher as the majority of individuals have circulating antiCandida antibodies [4]. Under conditions that permit outgrowth or invasion, C.
albicans has the potential to cause infection and disease. Therefore, a balanced
immune response is required to defend against damaging infections, while
tolerating mucosal colonization. However, the mechanism controlling the hostpathogen relationship is relatively unknown.
Previous studies by Noverr et al. demonstrated the ability of C. albicans to
produce immunomodulatory molecules called oxylipins, which are similar in
structure and function to host eicosanoids.

Eicosanoids are a family of lipid

immune signaling compounds that include the prostaglandins and leukotrienes.
Specifically, C. albicans produces a compound that cross reacts with mammalian
prostaglandin E2 (PGE2), called PGEx [2].

Very little is known about the

immunomodulatory roles that PGE2 or PGEx plays during candidiasis.

Our

hypothesis is that production of oxylipins by both fungi and host are crucial in
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modulating the microbiology of the fungus and the host-pathogen interaction in
favor of chronic infection or pathogenesis. The goal of this thesis project was to
investigate the roles of both host and Candida produced eicosanoids during hostpathogen interactions both in vitro and in vivo.

This involved investigating

interactions with phagocytic and antigen presenting cells and how these cells
influence downstream adaptive immune responses during systemic infection. In
addition, we investigated effects of host eicosanoids and eicosanoid inhibitors
during pathogenesis of mucosal and systemic infections. The results of these
studies are clinically significant and may help direct novel pharmacotherapeutic
strategies to treat fungal infections.

Virulence Attributes of Candida albicans.

C. albicans is an opportunistic

pathogen that normally resides at mucosal surfaces asymptomatically.
Therefore, it is not under selective pressure to develop traditional virulence
factors found in professional pathogenic microbes.

Virulence factors in C.

albicans are often the factors that allow the organism to persist within the host at
mucosal surfaces and systemically. In fact genetic deletion of many Candida
“virulence factors” results in avirulence during both mucosal and systemic
infection models. It may therefore be more appropriate to define virulence in
terms of traits required for survival within the host and evasion from host
defenses.

Virulence traits in Candida includes adhesion to host surfaces,

morphogenesis, biofilm formation, antigenic or phenotypic switching, tissue and
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non-phagocytic invasion (via proteases and phospholipases), and intracellular
survival strategies [5-7].

Morphogenesis
C. albicans is polymorphic and has the ability to grow both as yeast
(blastospores), and as hyphae and pseudohyphae (filamentous form). The
conversion from yeast to hyphae is induced by environmental conditions such as
growth at 37°C, serum, pH > 6.5, D-glucose, CO2, and nitrogen and carbon
starvation (reviewed in [8]). In addition, C. albicans produces quorum-sensing
compounds that control morphogenesis. At high population densities, farnesol
accumulates and represses hyphal formation, whereas tyrosol promotes
germination at low population densities when farnesol concentrations are low [9].
In addition, it was discovered that bacterial products influence morphogenesis.
Pseudomonas aeruginosa produces a 12 carbon compound called dodecanol,
which inhibits morphogenesis, indicating an antagonistic relationship. Another
study demonstrated that active serum fractions that promote hyphal formation
contain bacterial peptidoglycan (PGN)-like molecules [25]. Analysis of purified
bacterial products showed that synthetic muramyl dipeptides (MDPs), subunits of
PGN, can strongly promote C. albicans hyphal growth. Multiple signal
transduction pathways regulate hyphal development, including mitogen activated
protein kinase (MAPK) cascades, pH-dependent signaling cascades, and cAMPdependent protein kinase A (PKA) pathways [10]. These pathways sense and
respond to divergent and overlapping environmental signals. Therefore, C.
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albicans control of morphogenesis can be fine tuned within the various host
niches.
The yeast forms are more often associated with asymptomatic
colonization whereas the hyphal form is associated with infection and disease.
Genes that control hyphal morphogenesis are co-regulated with genes encoding
virulence factors such as proteases and adhesions [11]. The ability to switch
between yeast and filamentous forms is also required for virulence as mutants
that are “locked” in either the yeast form or the hyphal form are avirulent [11, 12].
One study demonstrated that there are distinct roles for both yeast and hyphae in
pathogenesis [13]. They engineered a strain that carries one copy of NRG1, a
key negative regulator of hyphal development, under the control of a tetracyclineregulatable promoter so the growth forms of the strain can be controlled in vivo.
Mice injected with this strain under conditions permitting hyphal formation
succumbed to the infection, whereas all of the animals injected under conditions
that inhibited this transition survived. Importantly, fungal burdens were almost
identical in both sets of animals, indicating that, whereas filament formation
appears to be required for the mortality resulting from a deep-seated infection,
yeast cells play an important role early in the infectious process by extravasating
and disseminating to the target organs. This indicates that hyphal formation is
required for mortality via an unknown mechanism. Therefore, this suggests that
there are morphotype specific factors and/or immune responses that influence
survival.

5
Biofilm Formation
Another role that morphogenesis plays in the lifestyle of C. albicans is in
the ability to form biofilms, which are complex aggregations of microbial cells
attached to a solid surface, marked by the excretion of a extracellular
polysaccharide matrix (ECM) [reviewed in [14-16]. Biofilm formation requires the
ability to undergo morphogenesis with germination being induced upon contact
with an appropriate surface [17, 18]. Mutants of C. albicans that are unable to
form hyphae also are unable to form vigorous biofilms.

In addition,

environmental conditions that induce hyphal formation also facilitate biofilm
formation. C. albicans readily forms biofilms on abiotic surfaces such as synthetic
polymers used in medical devices. In addition, recent studies using experimental
models of infection have shown that C. albicans forms biofilms on biotic surfaces
such as oral and vaginal mucosal tissues in vivo [19, 20].
Biofilm formation occurs in distinct developmental stages:

attachment,

proliferation, hyphal transformation, maturation, and dispersal [9, 21]. The
maturation stage involves a repression of yeast growth, and a proliferation of
hyphal growth elevated combined with secretion of ECM.

The matrix is

composed of carbohydrates, protein, phosphorus, hexosamines, and glucose;
however, a large amount of material remains uncharacterized [22].

Further

studies by Mukherjee et al. have indicated that the composition of ECM (the
protein and the carbohydrate component) varies depending on the biofilm
developmental stage [15]. Macromolecular studies have been difficult but one
study demonstrated the cell wall component -glucan could be detected in biofilm
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ECM [23]. This is of significance because -glucan is recognized by dectin-1, a
pathogen recognition receptor (PRR), and could influence interactions with the
host [24-26].
Studies have shown that C. albicans biofilms are highly heterogeneous in
terms of structural architecture, which varies greatly by the nature of the
substrate surface. For instance biofilms formed on polyvinyl chloride disc have
distinct composition compared to that formed on silicone elastomer or
polymethylmethacrylate denture strips [15, 27] .

Unlike the nature of the

substrate resulting in different composition of biofilms, different environmental
factors (pH, oxygen availability, fluid shear and redox-gradients) does not seem
to be playing role in designing the architecture of the C. albicans biofilms.
Similar levels of transcript profiles were detected from the biofilms growing under
different environmental conditions.
In terms of infection, Candida biofilms readily form on indwelling medical
devices and represent one of the main portals of entry for systemic and tissue
candidiasis [28]. It is estimated that the majority of microbial infections originate
from biofilms, with biofilm infection of indwelling medical devices being the single
most important cause of nosocomial bloodstream infections (BSI).

To

underscore this point, it is estimated that 250,000 - 500,000 device-related BSIs
occur annually in the US.

Among those infections, 10% are caused by C.

albicans, which has the highest mortality rate (40%) of all BSI causing organisms
[29, 30].

Another feature of C. albicans biofilms is that they are highly resistant

to antifungal agents [31]. The mechanism underlying this increased resistance is
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not well understood; however, poor antifungal penetration has been ruled out
[32]. Genomic studies have shown that biofilms exhibit unique gene expression
patterns compared with planktonic cells, including upregulation of multi-drug
resistance pumps [33-35]. The gene pathways that control biofilm formation are
still being dissected.

There is some overlap with pathways that control

morphogenesis; however, a specific biofilm regulator, Bcr1, is required for normal
biofilm formation and can still form hyphae.

Therefore, biofilms represent a

unique lifestyle for C. albicans, which requires significant investigation in terms of
pathogenesis.

Overview of the Immune Response to C. albicans Infections. C. albicans
causes both superficial mucosal infections and deadly systemic infections which
involve the bloodstream and tissues. The type of risk factors and appropriate
immune response to infection varies depending on the type of infection. C.
albicans resides at mucosal surfaces as a commensal organism, where immune
responses must be tightly controlled to both prevent overgrowth and infection but
also to prevent over-exuberant inflammatory responses.

Control of mucosal

infections and clearance of systemic infections require both effective innate and
adaptive immune responses. The inflammatory response to fungal infections
must be followed by resolution of inflammation, which is essential for limiting host
damage. Fungal infections tend to be chronic, which indicates that the immune
system

maintains

inflammation.

a

very

precarious

balance

between

tolerance

and
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Mucosal Infections
C. albicans is frequently isolated from the mucosal regions of vagina, oral
cavity and gastrointestinal tract and can be carried asymptomatically in healthy
individuals [36, 37].

Changes in the host environment can lead to fungal

overgrowth and/or imbalances in host immune responses leading to symptomatic
mucosal infection. Risk factors for mucosal infection are tissue specific and
include host factors (immunosuppression) and environmental factors (antibiotics
and hormones).

Vaginal infection:

About 75% of women have at least one incidence of

vulvovaginal candidiasis in their lifetime with about 5-10% recurrence rate [38,
39].

Antibiotic treatment, oral contraceptives, hormone replacement therapy,

pregnancy, immunosuppressive therapy are the several known predisposing
factors leading to this disease [38-40]. In case of vaginitis the resistance and
susceptibility is not dependent on adaptive immune responses. This is supported
by the fact that women with HIV infection, who are susceptible to oropharyngeal
candidiasis (OPC), were no more susceptible to vulvovaginal candidiasis (VVC)
than the healthy HIV- population [41]. In addition, experimental models show no
role for cell mediated or humoral immunity. In understanding why adaptive
immunity is not engaged in vaginal infections, studies have indicated that a
strong regulatory immune response is present.

Regulatory T cells (Tregs),

transforming growth factor  (TGF-) and plasmacytoid dendritic cells (DCs) were
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present at the vaginal mucosa, which can inhibit inflammatory T cell responses
[42-44]. Regulatory T cells (Treg) are responsible for dampening inflammation
and promoting tolerance at mucosal surfaces via production of IL-10 and TGF-β
[45]. In addition, homing receptors on T cells in the draining lymph nodes were
down-regulated, indicating an inability to traffic to the vaginal mucosa.
Instead, it is believed that susceptibility is controlled by innate immunity.
The vast majority of symptomatic infections in women have increased neutrophil
infiltrate that correlated with the observed symptoms of vaginitis. In fact,
neutrophil infiltration showed a positive correlation to high vaginal fungal burden.
Conversely, those women in these studies who presented as asymptomatic
showed no evidence of neutrophil infiltration or inflammation. However, these
neutrophil have defective antifungal activity and therefore may contribute to
pathology rather than control infection. It has been proposed that a threshold
number of C. albicans cells is necessary to stimulate the neutrophil response and
symptoms of disease, but that the threshold needed varies depending on the
individual [46]. Vaginal epithelial cells also exert a fungistatic activity, which is
reduced in women with recurrent vaginitis [47]. In addition, these epithelial cells
can sense and respond to Candida cells and signal the chemotaxis of neutrophils
[48]. Therefore, differences in the sensitivity of vaginal epithelial cells may be
involved in determining susceptibility.

Oral infection: There are several types of oral candidiasis including OPC, which
is associated with T cell deficiency (HIV and neonates), and denture stomatitis,
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which is associated with a contaminated indwelling device but occurs in
otherwise healthy individuals. There is a lack of studies investigating denture
stomatitis.

One study demonstrated that both Th1 and Th2 cytokines are

produced in patients [49].

Therefore, disease is not likely due to a Th1

deficiency. Instead the Th1-type immune response is active but seemingly fails to
resolve or protect against infection. This could be due to the serial feeding of the
tissue with Candida as a biofilm on the denture material resulting in the chronic
inflammation associated with infection.
OPC involves infections of the palate, tongue and buccal mucosa and can
either be pseudomembranous (thrush) or erythematous and is considered an
AIDS defining illness [50]. Dissemination of infection generally does not progress
from oral infections. While it is clear that CD4+ T cells and adaptive immunity is
required for defense against OPC, innate defenses also play a role in controlling
fungal growth.

Epithelial cells can inhibit up to 80% of Candida growth by

involving static mechanisms or production of cytokines [51-58].

In addition,

saliva contains antimicrobial secretions consisting of calprotectin, β-defensins,
and histatins [59, 60]. Along with epithelial cells, neutrophils are described to
play role in innate immune responses though it is controversial [8, 61]. Studies
have demonstrated reduced numbers of Langherhan cells in patients with
frequent oral candidiasis incidences indicating that DCs might have some key
role to play towards clearance of Candida. [62].
Adaptive immune responses largely involve cell-mediated immunity, while
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humoral immunity does not appear to play a role in protection against or
susceptibility to OPC [63]. Clinically, OPC is most common in HIV+ patients
when CD4+ cell numbers drop below 200 cells/μl [64]. Overall, the prevalence of
OPC depends on the status of the local immune mechanisms. Indeed some
individuals with <200 CD4+ cells/μl never have OPC while others have recurrent
episodes of OPC. Under conditions of CD4+ T cell deficiency it has been
proposed that aside from innate defenses, CD8+ T cells help control C. albicans
and that susceptibility is associated with defects in trafficking of cells to the site of
infection [65]. In deciphering how CD4+ T cells control oral C. albicans levels, it
was proposed that a Th1 response is required.

However, recent studies in

experimental models have indicated the role of Th17 cells as well towards
inducing protection against oral candidiasis [66]. Interestingly, knockout mice
lacking IL-23 or IL-17R (Th17-deficient) were highly susceptible to OPC, whereas
mice lacking IL-12 (Th1-deficient) were relatively resistant to infection.

Gastro-intestinal infection: Under normal conditions, humans are colonized with
about 1014 microorganisms in the GI tract, most of them being bacteria. Fungi
are also important part of the microbiota and Candida is one of the most
commonly isolated genus. Under healthy host conditions, the Candida carriage
rate inside the GI tract varies somewhere from 30-70% [2, 3]. Increases in GI
colonization with Candida combined with immunosuppression can lead to spread
into the bloodstream, an infection known as candidiasis of endogenous origin
[67-70]. Risk factors include antibiotic treatment and parenteral nutrition, which
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alter the bacterial microbiota leaving a niche for Candida overgrowth. In addition,
patients undergoing immunosuppressive treatment and cancer patients are
particularly at risk of developing GI candidiasis.

One of the major problems

associated with GI infection is that it is not clinically detected during the early
stages of infection due to inconspicuous symptoms and the inability to
differentiate commensal Candida from a pathogenic type.
Both innate and adaptive immune responses are important for protecting
against gastro-intestinal candidiasis. The key immune cell players involved in
initiating potent innate immune responses are NK cells, macrophages and
neutrophils.

This was verified when gnotobiotic immunodeficient mice with

defects in granulocytic cells showed susceptibility to candidiasis.

However,

Candida-specific T cell and antibody responses were mounted, and eventually
cleared the infection [71]. Treatment with the inhibitors of nitric oxide synthase
(NOS) increased the magnitude of GI candidiasis severity. However, peroxynitrite
was the responsible player, as nitric oxide is not candidacidal directly [71].
These studies indicate that these reactive oxygen species released by the
phagocytes are important in controlling Candida.
Regarding adaptive immunity, studies using congenitally athymic T cell
deficient (nu/nu), severe combined immunodeficient (SCID; no T or B cells) mice,
or mice specifically lacking α/β or γ/δ T cells have shown that T cells are critical
for effective protection against GI candidiasis (6, 9, 31, 104). Mice with T cell
deficiencies were more susceptible to GI tract infection, but were not susceptible
to sublethal intravenous challenge or dissemination from the GI tract. Various
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studies have indicated that during GI candidiasis, Th1 responses are associated
with protection whereas the Th2 responses induce non-protective phenotype [7276]. Antibody mediated protection against GI candidiasis have not been reported
and mice lacking B cells are not susceptible to infection [77]. A study indicated
that oral immunization had no role in decreasing the colonization of GI tract [78].
More recent studies have investigated the role of DCs in GI infections.
Using an experimental murine model, it was demonstrated that Peyer’s patch
DCs can discriminate between yeast and hyphal forms of C. albicans and
promote differentiation of inflammatory (Th17/Th1) and tolerogenic DCs
(Th2/Treg), respectively [79]. In addition, exacerbation of a Th17 response,
characterized by uncontrolled inflammation and dampening of Th1 responses via
IL-23 and IL-17, also leads to a worsening of fungal disease in the GI tract [79].
These observations contradict previous studies which demonstrated that yeast
promote Th1 responses while hyphae promote Th2 responses from human
dendritic cells [80]. It is possible that these differences are due to differences in
dendritic cells or the experimental model used.
In the context of C. albicans mucosal infections, Tregs are required for
effective control of protective Th1 inflammation, which prevents eradication of
infection. This not only facilitates generation of memory immunity but also limits
pathological inflammatory responses to persistent colonization [81, 82].
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Systemic Infections
Systemic candidiasis is an infection associated with high morbidity and
mortality. Infections are often misdiagnosed, and delayed treatment combined
with drug resistance has resulted in a 40% of crude mortality rate [30, 83, 84].
The total number of Candida sp. cases in the U.S. ranges from approximately
10,500 to 42,000 infections per year and is the fourth leading cause of
bloodstream infections [85]. At present overall systemic candidiasis rates are on
a rise and are associated with enormous amounts of health and economic losses
[86]. Risk factors include immune deficiency associated with neutropenic, organ
transplant, and cancer patients, use of immunosuppressive drugs, and indwelling
medical devices. There are two major pathways by which C. albicans may enter
the bloodstream: penetration from the GI tract into blood vessels and direct
transmission via intravascular catheters [86-88].
Cells of the innate immune response represent the first line of defense
against C. albicans infections and include effector cells with potent antifungal
activity: neutrophils and macrophages [89-91]. While neutrophils generally kill
via

secreted

enzymes

and

oxidative

intermediates,

macrophages

phagocytose C. albicans and kill via lysosomal and oxidative pathways.

can
In

addition, innate immune cells serve in the initial recognition of C. albicans via
pathogen recognition receptor (PRR) signaling.

PRRs, including toll-like

receptors (TLRs) and lectins recognize cell wall components of C. albicans.
Innate cells express PRRs and respond by secreting a variety of immune
signaling molecules to direct adaptive responses in a microbe-specific manner.

15
In particular, macrophages and DCs play important roles in PRR recognition of
C. albicans and serve as antigen presenting cells, linking innate and adaptive
immunity.
Neutrophils are potent antifungal cells and play a key role in the
prevention of fungal growth and the invasion of tissues. Defects in neutrophil
number and function have been consistently implicated in the pathogenesis of
disseminated candidiasis [92, 93]. In particular, defects in oxidative defenses of
neutrophils such as myeloperoxidase (MPO) or NADPH oxidase increase
susceptibility to systemic infection [94, 95].

C. albicans first encounters

neutrophils in the bloodstream during systemic infection. Neutrophils inhibit C.
albicans growth, enhance the fungal response to overcome nitrogen and
carbohydrate starvation, and induce the expression of a large number of genes
involved in the oxidative stress response [93]. In addition, neutrophils are the
primary antifungal cell recruited to the site of tissue infection. Studies have
demonstrated that TNF-α, IL-6, and G-CSF play an important role in the
recruitment of PMNs at the site of invasive Candida infection [96-98].

In the

absence of either TNFα or IL-6, the course of experimental disseminated
candidiasis is more severe, due to defective PMN recruitment [99]. Treatment of
mice with recombinant G-CSF (rG-CSF) leads to a significantly reduced mortality
and fungal burden during disseminated candidiasis [100]. This is likely due to the
ability of this cytokine to promote proliferation and differentiation of neutrophils
from bone marrow. In terms of chronic infections, the role of neutrophils may be
primarily as a source of pro-inflammatory cytokines, since these cells have been
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shown to produce TNFα, IL-6 and IL-12 upon stimulation with virulent Candida
strains, but not avirulent, hyphal defective mutants strains[97].
Macrophages also play an essential role during systemic candidiasis. In
an experimental model of systemic candidiasis, macrophage depletion resulted in
delayed clearance and high kidney fungal burden [101]. Macrophages can kill
Candida via oxygen-dependent or independent pathway [102]. Oxygen
dependent pathways include production of both reactive oxygen and nitrogen
intermediates (ROI, RNI). In particular, nitric oxide (NO) has strong antifungal
activity; however, C. albicans can evade host defense by suppression of
NO/superoxide radical production by stimulated macrophages [103-105].
Furthermore, what were thought to be two independent pathways, i.e., nitric
oxide and superoxide anion, have now been shown to combine to form a potent
macrophage candidacidal molecule, peroxynitrite. Oxygen independent pathways
are less well studied. However, upon phagocytosis of C. albicans, yeast forms
can germinate and lyse macrophages [106]. Therefore, whether the macrophage
or the fungus prevails is dependent on several factors, including the type of
macrophage and activation state. In contrast to neutrophils, which are important
in resistance to early stages of C. albicans infections, differentiated macrophages
activated by cytokines such as IFN-γ participate in the acquired resistance of
hosts with C. albicans-specific, cell-mediated immunity.
DCs are one of the most potent antigen presenting cells and has the
potential to educate the naïve T cells to further induce adaptive immune
responses. DCs arise from the bone marrow progenitor cells called common DC
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precursors and migrate via blood to both primary and secondary lymphoid
tissues as well as peripheral tissues (mucosal surfaces, skin). Immature DCs are
characterized by their low endocytic activity and inability to educate naïve T-cells.
Upon phagocytosing antigens or pathogens, they are activated to become
mature DCs, which express activation markers CD80 and CD86, co-stimulatory
molecules B7.1 and B7.2, as well as high levels of MHC class I and class II
molecules. Activated mature DCs then migrate to the regional lymph nodes via
the afferent lymphatic vessels where they lose the ability to further uptake
antigen. Mature DCs secrete immune signaling compounds and interact with
naïve T cells and influence differentiation of different T cell subsets.
There are two main subsets of DCs defined by cellular lineage markers:
classical or myeloid type DCs (CD11c+ CD11b+), and plasmacytoid DCs (CD11c+
B220+). Myeloid DCs (mDCs) are the typical DCs displaying dendritic extensions
and having antigen-presentation function in steady-state [107]. Also known as
lymphoid organ-resident DCs, mDCs are derived from blood-borne progenitors
and are found in the thymus, spleen, and lymph nodes, where their actions are
restricted to the organ in which they reside. In addition, mDCs are more prevalant
in the body and are found in the regions like mucosal linings and skin tissue [63,
108-110]. Plasmacytoid DCs (pDCs) lack dendrites but have a plasmacytoid
shape. Unlike mDCs, pDCs are very thinly distributed in the body and they
normally reside in lymph nodes, blood and thymus. Signaling via various
molecules cause their recruitment at the site of infection. pDCs express lower
levels of MHC class II and are much less efficient at inducing T-cell proliferation
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compared with mDCs [111]. Mature DCs educate the naive T cells into Th1,
Th2, Th17 or Treg phenotype [112, 113]. In terms of Candida systemic infection,
a Th1 response results in protection and clearance, while a Th2 response is nonprotective [114]. Th1 responses require production of phagocyte activating proinflammatory cytokines such as IFN-γ IL-12, IL-6, and TNF-α [74, 115-118].
Tregs or Th3 cells have potent anti-inflammatory activities and aid both
controlling inflammation and in resolution of inflammation after infection [119,
120]. Tregs are involved in suppressing inflammation and promoting tolerance
via contact dependent and independent mechanisms.

In particular, they are

associated with secretion of anti-inflammatory cytokines IL-10 and TGF-β [56].
There are several subsets of Tregs: CD4+CD25+ intrinsic Tregs, and Tregs
induced in the periphery. The majority of the time C. albicans exists as a
commensal, not a pathogen. In this situation, it would benefit the host not to elicit
an inflammatory immune response, but instead maintain tolerance via generation
of Tregs. However, Tregs could exacerbate disease by dampening protective
inflammatory responses in the case of systemic infection [121]. Therefore,
dendritic cells and other antigen presenting cells must be able to quickly
discriminate between commensal and pathogenic Candida growth states and
initiate the proper T cell-mediated response.
Th17 cells have a distinct lineage and cytokine profile compared with Th1
and Th2 cells. Naïve T cells differentiate into Th17 cells in the presence of a
combination of TGF-β, IL-6, IL-1, and IL-21, while IL-23 is essential for Th17 cell
expansion and function. Th17 cells secrete a unique profile of cytokines including
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IL-17 (IL-17A), IL-17F, IL-21, IL-22 [66]. Production of these cytokines induces
neutrophil activating factors, antimicrobial peptides, and acute response proteins
(reviewed in [122]).

In terms of systemic candidiasis, the Th17 response is

required for protection as mice lacking IL-17 receptor are more susceptible to
acute intravenous infection [123, 124].

This was associated with reduced

neutrophil recruitment. In addition, vaccination with a hyphal adhesin protein
induced a protective Th17 response and Th17 cells enhanced phagocytic killing
of C. albicans in vitro [125].
DCs have the ability to distinguish and discriminate between the two
different Candida morphotypes, i.e., hyphae and yeast form. Coordinated
signaling via TLRs results in either pro or anti-inflammatory responses by
production of different cytokines which will cause changes in downstream
signaling molecules to influence adaptive immune responses [126]. Recognition
of DCs with yeast form of Candida results in stimulation of type 1 cytokines
(DC1). This type of interaction involves signaling via TLR4 complexes. Hyphal
form of Candida signals via TLR2 and cause induction of type 2 cytokines (DC2).
Other studies have indicated that interaction with hyphal forms inhibits the
maturation followed by activation of DCs [126-128].

Studies by Graaf et al

demonstrated that when C. albicans-pulsed DCs were injected into the mice, the
yeast-pulsed DCs caused a protective response whereas the mice which were
injected with hyphae-pulsed DCs lead to a non-protective response [127].
Further, recent studies have demonstrated that C. albicans signaling via
TLR2 induces production of host PGE2, which can cause inhibition of innate
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responses for antifungal defenses [127]. This indicates that eicosanoids shift the
immune response towards that of a non-protective type.

Prostaglandins

produced by both host and fungal cells also enhance morphogenesis in C.
albicans suggesting that eicosanoids could participate in modulating the immune
responses by both influencing Candida and DC biology [77, 129].

Thus,

depending on the morphotypes of Candida (yeast or hyphal form), the DCs have
the ability to modulate the immune responses.

Immunoregulation by Eicosanoids

Host eicosanoid production.
Eicosanoids are one of the most abundant subfamily of oxylipins, which
are oxidized fatty acids [47].

Eicosanoids are made up of 20 carbon PUFA

metabolites that include the prostaglandins (PGs) and leukotrienes (LTs).
Eicosanoids, whose major precursor is arachidonic acid, potent modulators of
immune responses [130, 131].

Eicosanoids can be divided into various

subfamilies, the main one being prostanoids which are products of a
cyclooxygenase (COX). Various subfamilies of the prostanoids are differentiated
based on the region of the oxygen substitution in the cyclopentane ring, and also
by a number, representing the number of cis double bonds in the lipids [132].
For example, a prostaglandin of the E class derived from arachidonic acid will be
denoted as prostaglandin E2 (PGE2).

21
The

polyunsaturated

fatty

acids

are

sequestered

in

membrane

phospholipids and are released upon receiving various endogenous or
exogenous signals.

Upon the release of precursor fatty acids from the

membrane, they are re-esterified or enzymatically converted to eicosanoids.
These eicosanoids generally have a very short half-life as they are immediately
hydrolysed or undergo spontaneous metabolic inactivation, which could take
place by the process of ω-hydroxylation, fatty acid β-oxidation and enzymatic
dehydrogenation. As a result of these processes, eicosanoids are generally not
stored in the cells. During the initial steps in biosynthesis of eicosanoids, 20
carbon PUFA precursor (generally arachidonic acid) are released from the
membrane phospholipids by the action of an enzyme called phospholipase
(specifically phospholipase synthases A2 in mammalian cells) [131]. The initial
step of prostaglandin biosynthesis is catalysed by COX (also known as
prostaglandin H synthase) which are bifunctional heme-dependent enzymes
[133]. In mammals, there are two COX enzymes, COX-1 being constitutive form
and COX-2 being inducible form [131]. These enzymes are inhibited by a class of
drugs known as NSAIDs (non-steroidal anti-inflammatory drugs), which includes
aspirin, indomethacin, etc.

The different classes of prostaglandins are then

synthesized by specific synthases and hydrolases.
PGE2 is one of the most well studied prostaglandins and is a pleiotropic
signaling molecule. PGE2 signals via four receptors on host cells: EP1, EP2,
EP3, and EP4 [134]. In terms of immune regulation during infection, PGE2 is
associated with anti-inflammatory activities such as inhibition of effector functions
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of inflammatory cells. These include inhibition of mediator release from DCs,
macrophages, neutrophils, mast cells, basophils and lymphocytes [135]. Studies
have shown that PGE2 can interfere with DC maturation and cytokine secretion,
events required for migration to T cell areas and subsequent T cell education and
activation [46, 136, 137].

In addition, PGE2 and other eicosanoids can

downregulate macrophage functions including phagocytosis [9, 138-140].

To

summarize the different roles of PGE2 that it plays towards immune cell
modulation are to suppress macrophage cytokine and chemokine secretion
[141], inhibition of IL-12 and IFN-γ production by NK cells [141, 142], inhibition of
T-cell proliferation [71, 143], enhancement of

IgE class switching by B-cells

[144], up-regulation of antigen-induced mast cell degranulation [145], inhibition
of lymphocyte-endothelial cell interactions etc.
Eicosanoid production by host cells can also be influenced by the
interaction with fungal pathogens.

C. albicans induces activation of COX-2

transcription and the production of host PGE2 synthesis in macrophages,
splenocytes, and endothelial cells [146-148]. The ability to control or clear
Candida infection is dependent on the intensity of the inflammatory response
(Th1 vs Th2). Excess of PGE2 is shown to be associated with prevention of
synthesis of TNF-α and IL-12 and aids in the release of Th2 attracting cytokines
like IL-10. IL-10 is an important cytokine in regulating immune response and
plays key role in maintaining DCs in an immature state [72, 149]. Recent studies
have indicated an increased level of PGE2 production from the vaginal lavage
fluids from recurrent vulvovaginal patients [150]. This suggests that fungal
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manipulation of host eicosanoid production may be one strategy the organism
uses to subvert the immune system.

Candida eicosanoid production
The potential for eicosanoid production in medically important fungi had
been overlooked until recently. C. albicans causes release of arachidonic acid
from host tissues, which could be used for eicosanoids production [149, 151].
Candida produces both endogenous oxylipins as well as novel eicosanoid
products from exogenous arachidonic acid [77, 148]. A novel eicosanoid product
was detected, 3,18-diHETE, which is related to the 3-HETE product detected in
the lipomycetaceous fungi.

By immunofluorescence, endogenous eicosanoid

products were found in hyphae, but not in yeast forms, suggesting that this
product may be involved in morphogenesis.

The production of this novel

eicosanoid could be inhibited by aspirin, which also suppressed the growth of the
yeast form and prevented the yeast to hyphal transition of C. albicans [152].
A fungal oxylipin was isolated from Candida that exhibits cross-reactivity
with host PGE2. This compound, termed PGEx, is bioactive on mammalian cells
in vitro similar to PGE2, indicating the fungal oxylipins can modulate host immune
responses [77]. Fungal PGEx inhibited chemokine production, TNF- production,
and splenocyte proliferation while up-regulating IL-10 production. In terms of
effects on C. albicans, host PGE2 and fungal PGEx enhance C. albicans
morphogenesis, and up-regulated hyphal specific genes [77, 129].
oxylipin production is also upregulated during biofilm formation [153].

Candida
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C. albicans does not possess arachidonic acid when grown in vitro.
Therefore endogenous PGEx must be structurally distinct from host PGE2.
Because PGEx works similar to PGE2, it is likely that the ring group which is
recognized by EP receptors is similar, but the overall carbon length in shorter.
However, supplementation of C. albicans cultures with exogenous arachidonic
acid significantly increases PGEx production [154]. Therefore, PGEx derived
from arachidonic acid was analyzed to determine whether it is authentic PGE2.
Analysis of PGEx using LC-MS/MS determined that it possesses an identical
mass and elution time as commercial PGE2 standard. Further analysis using
MS/MS revealed that the fragmentation pattern for the PGEx and PGE2 standard
were identical [155]. This study was indicative of the fact that C. albicans can
synthesize authentic PGE2. Hence, C. albicans can synthesize both endogenous
PGEx and PGE2 from exogenous archidonic acid. In terms of levels of
production, in the presence of arachidonic acid, 99% of PGEx is PGE2.
Treatment of C. albicans with various COX inhibitors decreases fungal
prostaglandin production [156].

In vitro studies have also demonstrated that

COX inhibitors (aspirin, etodolac, diclofenac, celecoxib, nimesulide, ibuprofen,
and meloxicam) inhibit morphogenesis and biofilm formation [157]. In addition
aspirin reduces damage to host cells infected with Candida by inhibiting
extracellular fungal lipases [158]. Unlike mammalian eicosanoid production, little
is known about the genes involved in the pathway during prostaglandin formation
in fungi. This is due largely to differences between fungal and mammalian
enzymes at both the nucleic and amino acid sequence level. It was found that a
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C. albicans fatty acid desaturase homolog (Ole2) and a multicopper oxidase
homolog (Fet3) play roles in prostaglandin production, with mutant strains
exhibiting reduced PGE2 levels compared with parent strains.
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CHAPTER 1
Effect of PGEx and PGE2 on C. albicans Interactions
with Dendritic Cells in Vitro and In Vivo
ABSTRACT
Candida

albicans

produces

an

immunomodulatory

oxylipin

from

arachidonic acid that is structurally identical to host prostaglandin E2 (PGE2),
called PGEx.

In terms of host immune responses, PGE2 can promote Th2

responses, which are non-protective against fungal infection.

Dendritic cells

(DCs) are potent antigen presenting cells and reside at mucosal and lymphoid
tissues and play an integral role in directing adaptive cell mediated immune
responses.

We investigated the effect of PGE2 and PGEx on DC maturation

and cytokine production at early and late time points in a DC cell line and with
murine bone marrow derived DCs.

The ability of stimulated DCs to drive

adaptive responses against systemic C. albicans infection was tested by DC
vaccination.

In the presence of hyphae, PGE2 promoted early Th2 cytokine

production (2h) as well as increased levels of maturation marker CD86 on the DC
cell surface at 18 h.
production at 18 h.

Both PGE2 and PGEx suppressed Th1 cytokine and
The only notable difference between yeast and hyphae

pulsed DCs was in host cell PGE2 production. Vaccination with yeast-pulsed
DCs but not hyphae pulsed DCs lead to protective against systemic infection,
with reduced fungal burden in the kidneys. However, treatment with either PGEx
or PGE2 abrogated the ability of yeast pulsed DCs to induce protection. The lack
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of protection was associated with inhibition of Th1 cytokines and increased Th2
cytokines in the spleen.

Locally, exacerbated Th2 and Th17 cytokines were

detected in the kidneys of mice that were not protected against systemic
infection.

This indicates that host PGE2 or fungal PGEx can shift adaptive

responses in favor of the pathogen and that uncontrolled Th17 responses are
detrimental during systemic infection.
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INTRODUCTION

Candida

albicans

poses

a

significant

clinical

threat

to

both

immunocompetent and immunocompromised individuals. Chronic colonization at
mucosal surfaces with Candida is common, with carriage rates among healthy
adults ranging from 30-70% [2, 3]. Mechanisms by which Candida persists at
mucosal surfaces in the face of an adaptive immune response are relatively
unknown.

Mucosal persistence can lead to infection, with the severity of

Candida-associated diseases ranging from superficial mycoses to systemic
candidiasis. Systemic infections are very difficult to treat and account for 40% of
crude mortality rate [159].
C. albicans produce immunomodulatory bioactive lipids (oxylipins) that
are functionally similar to host eicosanoids, potent regulators of immune
responses [156, 160]. Candida produces both endogenous oxylipins as well as
novel eicosanoid products from exogenous arachidonic acid [156, 161]. A fungal
oxylipin was isolated from Candida that exhibits cross-reactivity with host PGE2.
This compound, termed PGEx, is bioactive on mammalian cells in vitro similar to
PGE2, indicating the fungal oxylipins can modulate host immune responses
[156].

Noverr et. al. reported that host PGE2 and fungal PGEx enhance C.

albicans morphogenesis [156, 162].

Candida oxylipin production is also

upregulated during biofilm formation [157]. Analysis of PGEx using LC-MS/MS
determined that it possesses an identical mass and elution time as commercial
PGE2 standard. Further analysis using MS/MS revealed that the fragmentation
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pattern for the PGEx and PGE2 standard were identical [154]. This study was
indicative of the fact that C. albicans has the potential to synthesize authentic
PGE2. Hence, C. albicans can synthesize both endogenous PGEx and PGE2
from exogenous arachidonic acid. The fact that both the host and yeast can
produce similar immunomodulatory signaling molecules suggests that host and
pathogen can participate in cross-species communication.

Further, oxylipins

may enable Candida to modulate immune responses in favor of persistence and
infection.

The role of Candida oxylipins in host-pathogen interactions and

Candida biology is not understood, nor have the biosynthetic pathways been
elucidated.
Dendritic cells (DCs) are one of the first types of immune system cells to
interact with C. albicans at the mucosal surface. The role of dendritic cells is to
discriminate between different types of microbes and direct appropriate immune
responses, linking innate and adaptive responses. Two types of DCs -myeloid
DC (mDC) and plasmacytoid DC (pDC) have been characterized and have
distinct origins and functions.

Studies have depicted that plasmacytoid DCs

(CD11c+ B220+) have been more involved with regulation of immunity and
tolerance of induction. On the other hand myeloid DCs (CD11c+ B220−) are
involved in the elevation of inflammatory responses [163] . DCs have the ability
to distinguish and discriminate between the two different Candida morphotypes,
i.e., hyphae and yeast form.

Coordinated signaling via TLRs results in either

pro or anti-inflammatory responses by production of different cytokines which will
cause changes in downstream signaling molecules to influence adaptive immune
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responses [164].

Recognition of DCs with yeast form of Candida results in

stimulation of type 1 cytokines (DC1). This type of interaction involves signaling
via TLR4 complexes.

Hyphal form of Candida signals via TLR2 and cause

induction of type 2 cytokines (DC2). Studies by Graaf et al demonstrated that
when candida-pulsed DCs were injected into the mice, the yeast pulsed DCs
caused protective response whereas the mice which were injected with hyphaepulsed DCs lead to a non-protective response [80]. DCs have the potential to
initiate specific T cell responses after interacting with pathogens. In terms of
Candida infection, a Th1 response results in protection and clearance, while a
Th2 response is non-protective, leading to disease [114]. Therefore, depending
on the type or nature of fungal morphology, i.e., yeast or hyphal form, the DCs
can regulate the T cell immunity caused by C. albicans during commensalism or
persistent infection, respectively.
PGE2 is a pleiotropic immune signaling compound and has effects on a
variety of cell types, including DCs. Exposure of DCs to PGE2 leads to inhibition
of type I cytokines (TNF-α and IL-12) and promotes release of type II cytokines
(IL-10) [36, 37].

Studies have shown that PGE2 can interfere with DCs

maturation and cytokine secretion, events required for migration to T cell areas
and subsequent T helper cell education and activation [165-167]. Thus, PGE2
may play role in promoting a non-protective immune response towards fungal
infection. The aim of our studies is to understand the effects of PGE2 and PGEx
on DC maturation and differentiation, and how these effects influence adaptive
immune responses during infection.
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MATERIALS AND METHODS

Mice. Female retired breeders or 6-8 week old mice of C57BL/6 strain were
obtained from Charles River Laboratories (Wilmington, MA). All mice were
maintained at an American Association for the Accreditation of Laboratory Animal
Care-accredited animal facility at Wayne State University (WSU) and housed in a
pathogen-free environment in accordance with the procedures outlined in the
Guide for the Care and Use of Laboratory Animals under an animal study
proposal approved by the WSU animal investigation committee.

C. albicans Strains and Culture Conditions. The C. albicans strain SC5314
used in this study is a prototrophic parental strain [168]. This strain was
subcultured from frozen stocks and grown overnight at 30°C in Sabouraud
dextrose agar (SDA) (Becton, Dickinson and Company, Sparks, MD). For liquid
cultures, isolated colonies from the SDA plates were cultured in Sabouraud
dextrose broth (SDB) with constant shaking. To obtain hyphal form, yeast form
of C. albicans was added to RPMI supplemented with 10% FBS at the
concentration of 1 x 106 Candida per ml of media. Hyphae were generated after
2 h incubation at 37°C.

JAWSII Cell line and Culture conditions. An immature dendritic cell line called
JAWSII (ATCC CRL-11904) was used for the purpose.

It is a GM-CSF

dependent dendritic cell line derived from the bone marrow of C57BL/6 mice
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[169-171].

The frozen vial containing the cells were thawed rapidly

(approximately 2 minutes) by gentle agitation in a 37°C water bath.

After

decontaminating the surface of the vial with 70% ethanol, the vial contents were
centrifuged at 130xg for 5 to 7 minutes.

Following this the pellet was re-

suspended with complete RPMI medium (Invitrogen) supplemented with 20%
fetal bovine serum and 5 ng/ml murine GM-CSF in a 25 cm2 tissue culture flask.
The cells, upon reaching a confluency of 80-90%, were subcultivated at 1:2 ratio
by transferring the floating cells by pipetting. Additionally, the attached cells were
removed by rinsing with 0.25% (W/V) Trypsin-0.53mM EDTA solution followed by
an incubation period of 5-7 minutes at 37°C incubator. All the cells were pooled
and centrifuged at 125 xg for 5 to 10 minutes. After discarding the supernatant,
the pellet was resuspended in fresh medium and transferred into a fresh new
flask. Following this, the flask was incubated at 37°C incubator in a 5% CO2 in
air atmosphere. Since these are very slowly growing cell line, the medium was
renewed at an interval of one time per week.

JAWSII Antigenic Stimulation and Harvest. The JAWS II cells were seeded in
six-well plates, each well at the concentration of 5 x 106 per well. They were than
stimulated with 1µM of PGE2 (Cayman Chemicals, Ann Arbor). An hour after
incubation, the cells were further stimulated with yeast or hyphae in presence
and absence of this prostaglandin at a MOI of 1. The control well was stimulated
with only PGE2. After an incubation period of 2 hrs Amphotericin B was added at
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a final concentration of 2.5 µg/ml. Further, the cells were trypsinized from the
surface using trypsin-EDTA in order to perform RNA extraction from them.

Oligo GEArray DNA Microarray. RNA was extracted from the antigen pulsed
JAWSII cells using RNeasy mini kit (Qiagen). A fraction of this RNA sample was
run on denaturing agarose gel to verify any possibility of degradation by looking
at the 18s and 28s ribosomal bands. A total of 0.1-3 µg RNA was used as a
starting material from which cDNA was synthesized using TrueLabeling primer
(Superarray Bioscience Corporation). Following this cRNA synthesis, labeling,
amplification and purification was performed using manufacturer’s provided kit.
Further, the biotin-labeled amplified cRNA was hybridized on a prehybridized (the
membrane was pre-wet in deionized water followed by replacing it with GEAhyb
hybridization solution and rotating the tube in oven for up to 72 hours) array
membrane inside a 5 ml disposable screw-top Hybtubes. At least 2 µg of biotinlabeled cRNA was added into the target hybridization mix. The hybridization step
was performed overnight inside a roller-bottle hybridization oven at 60°C with
continuous but agitation at 5 to 10 rpm. After hybridization steps, a series of
washing steps were performed mostly using various concentrations of SSC and
SDS solution.

After washing, chemiluminescent substrate was added to the

hybridization tube and rotated inside hybridization oven allowing the membrane
to incubate with the CDP-star for a brief period (2-5min). For image acquisition,
a CCD camera was used with an exposure period of 16 minutes and all the
images were saved as electronic files in a gray scale in 8 or 16 bit TIFF format.
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For data analysis of the arrays, an integrated web-based GEArray expression
analysis suite software was used. A two-fold value increase or higher compared
to the control was considered as significant increase.

Primer Design. The gene specific primers for mouse IL-4, IL-6, IL-10, IL-12 and
GAPDH used for RT qPCR (SABiosciences). These were experimentally verified
for their efficiency.

The catalog number for IL-4 is PPM03013E, IL-6 is

PPM03015A, IL-10 is PPM03017B, IL-12 is PPM03020E and GAPDH is
PPM02946E.

qRT-PCR Assay. qRT-PCR assay was performed using a MyiQ thermocycler
(Bio-Rad, Hercules, CA, USA). Each well contained a 25-µl reaction mixture that
included 12.5µL of 2× SYBR Green PCR Master Mix (Bio-Rad,), 1µl of gene
specific 10µM each of forward and reverse primers, 1µL of DNA template at
convenient dilution. The following thermocycling pattern was used: 95 °C for
10 min (to activate the hot start DNA polymerase; 95 °C for 15 s, 60 °C for 1 min
(40 cycles). A melting-curve analysis was performed at the end of each PCR
assay to control that a single PCR-product was amplified. qRT-PCR was carried
out on appropriate DNA dilutions in triplicate. For normalization, the mRNA for
mouse GAPDH was quantified in parallel for all other samples.

For data

analysis, difference between the critical threshold Ct values (ΔCt) for each
cytokine gene and the housekeeping gene was calculated.

The ΔΔCt was

obtained from the difference in the ΔCt values between the experimental and
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control genes. The fold change in CT between the cytokine gene expression
from the antigen pulsed dendritic cells and the change over unstimulated
dendritic cells was determined using the 2−ΔΔCt method [172].

Purification and Culture of Bone Marrow Dendritic Cells. Bone marrow cells
were obtained by flushing the femurs of the mice with RPMI supplemented with
10% FBS (Invitrogen). The cells were then incubated with RBC lysis buffer for 2
min followed by adding D-PBS. Following this, the cells were centrifuged at 1000
rpm and resuspended in complete RPMI (cRPMI) containing 5 mM HEPES
buffer, 0.3 mg/ml L-glutamine, 5.5 X 10-5 mol/L ß-mercaptoethanol, 100 U/ml
penicillin, 100 ug/ml streptomycin and 10% FBS.
For obtaining the plasmacytoid DCs (pDCs), the cells were resuspended
at the concentration of 106 cells/ml in complete medium supplemented with 200
ng/ml recombinant murine Fms-related tyrosine kinase-3 ligand (FLT-3)
(Prospec-Tany Tecnogene Ltd, Rehovot, Israel). After incubation of 9 days, the
cells were collected by removing the adherent and non-adherent cells by
vigorous pipetting with room temperature D-PBS [173].
For generating the myeloid or conventional type of dendritic cells, the
bone marrow cells were resuspended in complete RPMI at concentration of 1 X
106 cells/ ml and stored in 37°C, 5% CO2 incubator. On day 1, the non-adherent
cells were removed and resuspended at concentration of 5 x 105 / ml with RPMI
containing 20 ng/ml GM-CSF (Prospec-Tany Technogene Ltd, Rehovot, Israel)
and 20 ng/ml IL-4 (Shenandoah Biotechnology). Additional media and 40 ng/ml
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of each cytokines were added on day 3. On day 6, the cells were harvested,
pelleted and again resuspnded in 30 ml of cRPMI supplemented with 10 ng/ml
GM-CSF and 10 ng/ml IL-4. On day 8, the non-adherent cells were harvested
and used in experiments [174]

Flow Cytometry. For phenotypic analysis of DC subsets, surface markers were
analyzed using flow cytometry. The DC were washed three times in 200 µl cold
FACS buffer containing1% BSA / PBS, pH 7.2, 0.1% NaN3.

For purpose of

blocking Fcγ receptors, the cells were incubated in FACS buffer containing 5%
mice serum for 15 minutes at 4C. For staining, cell were washed three times
and resuspended at a concentration of 1 × 106 cells/ml in cold FACS buffer.
Cells were stained for 30 min at 4C in dark. Cells were stained with following
FITC or PE conjugated anti-mouse antibodies according to the manufacturer’s
instructions: CD86 (maturation marker), CD11b, CD11c, and B220 (ebioscience).
Myeloid DCs are CD11b+ CD11c+ and plasmacytoid DCs are B220+ CD11clo
CD11b-. Cells were washed twice with FA buffer and were then fixed with 4%
formalin. FITC- and PE-conjugated antibodies used for direct staining obtained
from ebiosciences are listed in
Table 1. A minimum of 20,000 events was acquired for each sample with a
FACScan flow cytometer (BD) and analysed using Flowjo software.

Isolation of fungal PGEx. C. albicans strain SC5314 was grown overnight at
37C in 10 ml RPMI containing 100 mM arachidonic acid. Culture supernatants
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were loaded onto a PGE2 affinity column (Caymen Chemical), washed, and
eluted according to the manufacturers’ instructions.

The eluates were dried

under a stream of nitrogen gas and resuspended in 500 µl PBS. PGEx
concentrations (approximately 20ng) determined using a PGE2 monoclonal
ELISA (Cayman Chemical, Ann Arbor).

Pulsing of DCs and culture of cells. DCs were harvested and washed twice in
sterile 1x PBS, counted, and resuspended in a final concentration of 1x106
cells/ml. Cells were plated into 6 well tissue culture treated plates in a volume of
6x106 cells/6ml/well. For pulsing, DC were exposed to unopsonized yeast or
hyphae at a DC:fungal cell ratio of 1:2. PGE2 (Caymen Chemical) or C. albicans
PGEx was added at a final concentration of 2nM. After 2 h incubation, 2.5

g/ml

amphotericin B was added to prevent fungal overgrowth. After pulsing, cells
were left for an additional 18 h in culture.

Supernatants were harvested for

analysis of immune mediators. Cells were washed and harvested for adoptive
transfer experiments.

Enzyme Linked Immunosorbent Assay. Cell culture supernatants (DCs and
splenocyotes) were analyzed for the following cytokines by ELISA: IL-4, IL-5, IL6, IL-10, IL-12, IL-13, IFN-γ, TGF-β, TNF-α, IL-23. The detection limits (pg/ml)
for the assays were <3.90 for IL-4, < 3.90 for IL-5, <3.90 for IL-6, < 31.25 for IL10, <15.62 for IL-12, <3.90 for IL-13, < 15.62 for IFN-γ, <62.5 for TGF-β, <7.81
for TNF-α and <7.81 for IL-23 (eBioscience). In addition, DC supernantants were
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also tested to analyze the levels of PGE2 (Cayman chemicals). The absorbance
of the plates was measured at 450nm using Multiskan Ex microplate reader
(Thermo Electron Corporation) and analyzed with Ascent Software.

Adoptive Immunization and Fungal Challenge. Pulsed and unpulsed BMDCs
were trypsinized and washed with 1x sterile PBS pH 7.4 at 1000 rpm.

They

were counted using a hemocytometer and intraperitoneally injected into the mice
at a concentration of 5 X 105 cells per mouse in 100 µl of sterile non-pyrogenic
PBS (Invitrogen) using a 27-gauge feeding needle attached to a 1-ml syringe.
Mice received either a single vaccination at day 0 or a double vaccination at days
0 and 7.

Four mice were used for adoptive transfer per each group.

7 d

following the last adoptive transfer of BMDCs, the mice were challenged by
intravenous tail injection with C. albicans at the concentration of 2.5 X 105
CFU/mouse in 250 µl of sterile PBS using a 30-gauge feeding needle attached to
a 1-ml syringe. Upon assessment of weight analysis for the purpose of
determining any incidence of cachexia, there was no significant decrease or
change in weights of the mice post systemic challenge with Candida for a period
of 7 days.

CFU Assay. To determine the amount of fungal growth in the organs of the
mice, the kidney and the liver were weighed and homogenized using a tissue
tearor.

Serial dilutions of tissue homogenates were made in sterile water and
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were plated onto sabouraud dextrose agar to determine the CFU per gram per
organ in each group of mice.

Splenocyte Harvest and Pulsing. Spleens were excised from the C. albicans
infected mice and the splenocytes were isolated from them. A 1:1 ratio of both
yeast and hyphal forms of C. albicans were used at MOI 1:2 to stimulate the
splenocytes. After 2 h of incubation, 2.5 µg/ml of amphotericin B was added to
prevent Candida overgrowth followed by further incubation of 16 h at 37°C, 5%
CO2 incubator.

The supernatants were collected and the levels of cytokines

were measured by ELISA.

Histological Analysis and Immunohistochemistry. Part of the organs (kidney
and liver) were excised and stored immediately in 10% buffered formalin for the
purpose of histology. Paraffin-embedded tissues of about 3-4 nm width were
stained with periodic acid-Schiff reagent and examined [149]. 5µm sections were
cut from paraffin-embedded kidney tissue blocks. Antibodies used along with
their respective companies purchased from and the dilution used are listed in
Table 2. For heat mediated antigen retrieval, sections were treated with for 20
min with 10mM sodium citrate buffer, 0.05% Tween 20, pH6.0. Incubation with
primary antibody was performed overnight at 4°C whereas incubation with the
biotin conjugated secondary antibody was performed for 30 min at room
temperature. To verify staining specificity, negative control slides or appropriate
isotype controls antibodies and at the same dilution as that of respective primary
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monoclonal antibodies were used.
IgM, IgG2b and IgG2a.

These isotype controls used were rat IgG,

Samples were analyzed by light microscopy using

Olympus BX41 microscope and Qcolor3 software tool.

Statistical Analysis. The Student’s t test (two-tailed, unequal variance) was
used to analyze the significance of differences between two experimental groups.
Significance was considered with a P < 0.05 or less. The data recorded are
representative of either two or three independent experiments.

41

Name of Antibody

Clone

Dilution

1.

Anti-mouse CD11b

RMMG-1

1:150

2.

Anti-mouse CD86 (B7.2)

GL1

1:160

3.

Anti-mouse CD45R (B220)

RA3-6B2

1:200

4.

Anti-mouse CD11c

N418

1:100

Table 1. List of antibodies and dilutions used for flow cytometry. All
antibodies were purchased from eBioscience.

Name of Antibody

Dilution

Company

1. IFN-γ (clone RMMG-1)

1:400

Abcam Inc., Cambridge, MA

2. IL-4 (clone 11B11)

1:100

Abcam Inc., Cambridge, MA

3. IL-6 (clone )

1:400

Abcam Inc., Cambridge, MA

4. IL-10 (clone NYRmIL-10)

1:200

Santa Cruz Biotechnology, Inc

5. IL-12A p35 (clone M-19)

1:200

Santa Cruz Biotechnology, Inc

6. IL-17 (clone 400210)

1:150

R & D Systems, Inc.

7. IL-23 (polyclonal)

1:200

Santa Cruz Biotechnology, Inc

8. Neutrophil (clone NIMP-R14)

1:100

Santa Cruz Biotechnology, Inc

Table 2. List of antibodies and dilutions used for immunohistochemistry.
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RESULTS

To determine the effect of prostaglandins on antigenic stimulation of DCs,
OligoGEarray was performed to examine early (2h) expression of cytokine
genes.

Through a simple technique of side-by-side hybridization method,

differential expression of the genes between the samples was compared. This
oligoarray profiles the expression of 113 genes, including cytokines in the Th1,
Th2, Th3 pathways, and other CD4+ T lymphocytes markers and transcriptional
factors that regulate the expression of these cytokines. There were also other
functional genes involved in immune cell activation, in the Th1 and Th2 type
immune responses, antimicrobial humoral responses, etc.

We attempted to

analyze early cytokine expression in primary bone marrow derived DCs;
however, the amounts of cells necessary to obtain high quality RNA precluded
using these cells. To obtain enough RNA to perform the oligoarray analysis, we
used an immature mouse dendritic cell line (JAWSII), which is a GM-CSF
dependent bone marrow derived cell line from C57BL/6. Th2 cytokines IL-4, IL10, and IL-13 were consistently upregulated in the presence of hyphae and
PGE2. In addition, pro-inflammatory cytokines IL-6 and IL-15 were upregulated
in the presence of hyphae and PGE2 (Table 3). On the other hand, a suppressor
of cytokine synthesis gene (SOCS-3) which was used as a control was
upregulated in the only PGE2 treated group. The confirmed the metabolic activity
of this compound during the in vitro studies. We were further able to confirm the
up-regulation of IL-4, IL-6, and IL-10 genes showed by the oligoarray technique
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using qRT-PCR (Figure 1). We observed no up-regulation of IL-12, which
indicates that up-regulated genes are not due to errors in RNA concentrations.
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E2

Y

Th2 Cytokines
IL-4
0.41
0.37
IL-10
0.67
0.64
0.73
0.73
IL-13
Pro-inflammatory Cytokines
1.68
1.09
IL-6
0.37
0.31
IL-15
Cytokine Suppressors
11.11
2.6
Socs3

Y + E2

H

H + E2

2.25
4.02
1.08

1.07
1.05
0.95

3.86
9.18
3.03

1.5
1.2

1.8
0.56

4.43
3.03

1.1

1.1

1.3

Table 3. Analysis of early cytokine expression in a DC cell line. JAWSII
cells were at a concentration of 5 x 106 per well and stimulated with PGE2 for 1 h
followed by pulsing with C. albicans yeast or hyphae at an MOI of 2. After 2 h,
RNA was extracted. Transcript levels were analyzed using a OligoGEarray kit
and analyzed using GEArray expression analysis suite software. A two-fold
value increase or higher compared to the control is depicted in the table.
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pDC

Th1
IL-12

mDC

Untreated

PGEx,
PGE2

Untreated

PGEx,
PGE2

++++



+



Similar



Similar

n/c

+

n/c

+++



n/c

Similar
+/-



Pro-Inflammatory
IL-6
Th-17
IL-23
Th2
IL-4
IL-10

Similar
+

Table 4. Relative expression of cytokines after stimulation of dendritic
cells with yeast or hyphae in presence or absence of prostaglandins.
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Figure 1. Analysis of early cytokines by quantitative real-time PCR in
JAWSII dendritic cell line. JAWSII cells were at a concentration of 5 x 106 per
well and stimulated with PGE2 for 1 h followed by pulsing with C. albicans yeast
or hyphae at an MOI of 2. After 2 h, RNA was extracted and pooled together for
each sample group. qRT-PCR was carried out on appropriate DNA dilution in
triplicate. For normalization, the mRNA for mouse GAPDH was quantified in
parallel for all other samples. For data analysis, difference between the Ct
values (ΔCt) for each cytokine gene and the housekeeping gene was calculated.
The ΔΔCt was obtained from the difference in the ΔCt values between the
experimental and control genes. The fold change in critical threshold (CT)
between the cytokine gene expression from the antigen pulsed dendritic cells
and the change over unstimulated dendritic cells was determined using the
2−ΔΔCt method Data is representative of two independent experiments
performed in triplicate.
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To confirm the results from studies with the DC cell line extend to primary
DC subsets, bone marrow derived plasmacytoid and myeloid type DCs were
used in vitro studies. There are several methods of generating DCs from bone
marrow in vitro. Culturing cells in the presence of GM-CSF generates myeloid or
inflammatory DCs, while FLT3-ligand preferentially expands plasmacytoid or
steady state DC populations [175-177]. Both types of DCs were characterized
for cell surface marker expression by performing FACS analysis as previously
described [178]. GM-CSF differentiated DCs (GM-DCs) were 86.3% CD11c+
B220- and 81.32% CD11b+ CD11c+ indicative of a myeloid DC phenotype (2a
and b). On the other hand, Flt-3L differentiated DCs (FL-DCs) were CD11clow
(57.7%) compared with GM-DCs (Figure 2c).

FL-DCs showed increased

expression of B220, with 45.7% were double positive for CD11c and B220, which
is indicative of a plasmacytoid DCs phenotype (Figure 2d) [175]. Most of the
remaining cells were CD11c+B220-. This is to be expected as FLT3-ligand
generates a heterogeneous population of DCs similar to steady state splenic
DCs.

Regardless, FL-DCs are functionally similar to plasmacytoid DCs in

experimental models [79, 179]. Therefore, we will refer to GM-DCs as mDCs and
FL-DCs as pDCs.

48

Figure 2. Characterization of bone marrow derived dendritic cells. Murine
bone marrow was harvested from C57BL/6 mice and cultured in the presence of
GM-CSF (mDCs) or FLT3-ligand (pDCs). A,B) Surface expression of B220,
CD11c, and CD11b on mDCs. C) Relative surface expression of CD11c on
pDCs (pDC-CD11clow) and mDCs (mDC-CD11chi). D) Surface epression of
CD11c and B220 on pDCs. The above data is representative of two independent
repeats of FACS analysis.
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To investigate the effect of C. albicans and prostglandins to induce
maturation of mDCs and pDCs in vitro, we analyzed CD86 expression, which is
upregulated during antigen presentation by dendritic cells. In unpulsed mDCs
16.3% of cells were CD11c+CD86+ and 13.3% of pDCs were B220+CD86+
(Figure 3). Upon stimulation of mDCs with Candida, CD86 expression increased
to 18.9% in the presence of yeast and to 21.42% in the presence of hyphae
(Figure 3a). Upregulation of CD86 was more dramatic with pDCs, with increases
from 13.3% to 36.44% with yeast and 46.8% for hyphae (Figure 3b). Addition of
PGE2 further increased CD86 expression in both DC types in the presence of
both yeast and hyphae. These results demonstrate exposure of mDCs and pDCs
to C. albicans and PGE2 induces maturation, with the greatest effects observed
in the presence of hyphae and PGE2.
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A) mDCs

B) pDCs

Figure 3. Maturation marker expression on mDCs and pDCs stimulated
with C. albicans and PGE2. Murine bone marrow was harvested from C57BL/6
mice and cultured in the presence of GM-CSF (mDCs) or FLT3-ligand (pDCs).
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Cells were stimulated with C .albicans strain SC5314 yeast (grown in SDB at
30°C) or hyphae (formed in 100% FBS at 37°C for 2h) at MOI of 2 in presence
or absence of 2 nM PGE2. After 2 h incubation, Candida was killed by adding 2.5
µg/ml of amphotericin B to the culture. Cells were harvested after 18 h and
stained with A) CD11c and CD86 for mDCs and B) B220 and CD86 for pDCs.
The isotype controls tested negative. The experiment was performed in
duplicate with two independent repeats with similar results.
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To analyze effects of PGE2 on early cytokine production in primary DCs,
we used qRT-PCR to measure changes in cytokines identified from the
oligoarray performed with the JAWSII cell line. Compared with yeast pulsed DCs,
hyphal pulsed DCs also tended to have higher IL-4 and lower IL-12 expression,
indicative of a shift towards a Th2 phenotype (Figure 4). Similar to what was
observed previously with JAWSII cells, treatment of hyphal pulsed DCs with
PGE2 resulted in the highest upregulation of IL-4 and IL-6, with concomitant
decreases in IL-12. Similar results were obtained with both mDCs and pDCs.
This indicates the PGE2 treatment can further promote pro-Th2 or pro-Th17
responses from DCs pulsed with hyphae.
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mDCs

pDCs

Figure 4. Analysis of early cytokines by quantitative real-time PCR in
mDCs and pDCS. Murine bone marrow was harvested from C57BL/6 mice and
cultured in the presence of GM-CSF (mDCs) or FLT3-ligand (pDCs). Cells were
stimulated with C .albicans strain SC5314 yeast or hyphae at MOI of 2 in
presence or absence of 2 nM PGE2 or PGEx. After 2 h, RNA was extracted and
pooled together for each sample group. qRT-PCR was carried out on appropriate
DNA dilution in triplicate. For normalization, the mRNA for mouse GAPDH was
quantified in parallel for all other samples. For data analysis, difference between
the Ct values (ΔCt) for each cytokine gene and the housekeeping gene was
calculated. The ΔΔCt was obtained from the difference in the ΔCt values
between the experimental and control genes. The fold change in critical
threshold (CT) between the cytokine gene expression from the antigen pulsed
dendritic cells and the change over unstimulated dendritic cells was determined
using the 2−ΔΔCt method. Data is representative of two independent experiments
performed in triplicate.
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Cytokine analysis of DC culture supernatants at a later time point (18 h)
was performed by ELISA to monitor phenotypic differentiation of both mDCs and
pDCs after antigenic stimulation (Figure 5). As reported previously, pDCs
secreted higher levels of the Th1 cytokine, IL-12, compared to mDCs [79].
Addition of either PGE2 or PGEx decreased the secretion of this cytokine in both
DC subsets. Similarly, a trend towards decreased production of pro-inflammatory
cytokine IL-6 was also observed in the presence of prostaglandins. The Th2
cytokine IL-4 showed similar cytokine secretion pattern from both types of
dendritic cells, which was slightly increased in presence of prostaglandin.
However, IL-10 was inhibited by prostaglandins in mDCs but slightly increased
with pDCs. Increased levels of the Th17 cytokine, IL-23, was observed in mDCs
as previously reported, which was inhibited in presence of prostaglandins [79].
The comparative summarization of cytokine induction pattern is listed in Table 3.
Overall, the data indicate that prostaglandins dampen Th1 cytokines, which could
result in generating a non-protective Th2 phenotype.
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mDCs

pDCs

*
*

*

*

*

*

*

*

*
*

Figure 5. Analysis of late cytokine production by ELISA in mDCs and
pDCs. Murine bone marrow was harvested from C57BL/6 mice and cultured in
the presence of GM-CSF (mDCs) or FLT3-ligand (pDCs). Cells were stimulated
with C .albicans strain SC5314 yeast (grown in SDB at 30°C) or hyphae (formed
in 100% FBS at 37°C for 2h) at MOI of 2 in presence or absence of 2 nM PGE2
or PGEx. After 2 h incubation, Candida was killed by adding 2.5 µg/ml of
amphotericin B to the culture. Cultured supernatants were harvested after 18 h
incubation and further used to assay for cytokines by ELISA. Data is
representative of three independent experiments performed in triplicates and
assayed in duplicate. * P < 0.05, prostaglandin treated vs. untreated cells.
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Figure 5 continued
mDCs

* *

*

*

pDCs

*

*

*

*
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Table 5. Relative expression of cytokines after stimulation of dendritic
cells with yeast or hyphae in presence or absence of prostaglandins.
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To determine the effects of C. albicans on prostaglandin levels in the DC
cultures, we tested the levels of PGE2 from the culture supernatants.

PGE2

levels were relatively low and did not significantly differ in any of the antigenic
groups at 2 h post-pulse (Figure 6). Because C. albicans was viable during this
period, PGE2 could be derived from C. albicans or the DCs. At 18 h post-chase
we observed increased production of PGE2 from the hyphae pulsed group in both
mDCs and pDCs (Figure 6).

This PGE2 is not produced from Candida as they

were killed after 2h with amphotericin B treatment. These data indicate that
hyphae induce significant PGE2 production from DCs.

59
mDCs
2h

18 h

*

pDCs
2h

18 h

*

Figure 6. Production of PGE2 from stimulated mDCs and pDCs. Murine
bone marrow was harvested from C57BL/6 mice and cultured in the presence of
GM-CSF (mDCs) or FLT3-ligand (pDCs). Cells were stimulated with C .albicans
strain SC5314 yeast (grown in SDB at 30°C) or hyphae (formed in 100% FBS at
37°C for 2h) at MOI of 2. Supernatant was harvested at 2 or 18 h post-pulse. For
the 18 h time point, after 2 h incubation, Candida was killed by adding 2.5 µg/ml
of amphotericin B to the culture. PGE2 levels were measured using a monoclonal
PGE2 EIA kit. Experiments were performed in triplicate and assayed in duplicate
and data is representative of two independent repeats. * P < 0.05, prostaglandin
pulsed vs. unpulsed cells.
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To further investigate the functional activities of the antigen stimulated
DCs in vivo, adoptive transfer experiments were performed. In initial
experiments, mice received a single adoptive transfer 7 d prior to systemic
challenge with C. albicans infection (Figure 7). To assess protection against
infection, kidney, blood, spleen and liver fungal burden was analyzed, which are
the major target organ during systemic infection. In mice vaccinated with antigen
pulsed mDCs, no protection was observed after adoptive transfer with antigen
pulsed cells (Figure 8a). However, the yeast pulsed pDC-vaccinated mice
showed close to a two-fold decrease in kidney fungal burden compared to the
other groups (Figure 8b). Interestingly, PGE2 or PGEx treatment abrogated
protective effect of yeast pulsed pDCs during vaccination (Figure 8b). This
indicates that mDCs do not impart the same type of protective response as
pDCs. Cytokines from restimulated splenic cultures were analyzed to
characterize the immune response in vaccinated mice. We observed increased
IL-6 production in the mice that received yeast-pulsed pDCs and decreased
levels in all other groups (Figure 8). While this indicated that a protective proinflammatory response may be elicited in yeast pulsed pDC mice, the splenic
response was relatively weak. No significant differences in IL-12, TNF-α, IL-4, IL10, or TGF-β were observed, with very low levels produced (data not shown).
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DC

Yeast or Hyphae
+/- 2 nM PGE2 or PGEx

2h
Wash Cells
Add AmpB
16 h

BMDCs
I.P. Injection
(5 x 105/mouse)
0

C. albicans
I.V. inoculation
(2.5 x 105/mouse)
7

14

21

Harvest

Figure 7. Dendritic cell vaccination or adptive transfer strategy. The antigen
pulsed dendritic cells were interperiteonally injected into the mice at a
concentration of 5X105/mouse on day 1. On day 7, this adoptive transfer with the
pulsed dendritic cells was repeated again. On day 14, the mice were challenges
with systemic infection by injecting them with 2.5X105 Candida through tail vein
injection. On day 21, the organs (spleen, liver, kidneys, blood) were harvested
from accessing protection.
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A) mDCs

B) pDCs

**
**
*

Figure 8. Assessment of protection from C. albicans infection following
single adoptive transfer with mDCs or pDCs. Antigen pulsed A) mDCs or B)
pDCs were harvested after 18h of stimulation. For vaccination, 5x105 cells were
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injected via the intraperitonial route in 6-8 week old C57BL/6 mice. After 7 d,
mice were inoculated by tail vein injection with C. albicans strain SC5314
(2.5x105 CFU/mouse). After 7 days post-inoculation, the mice were sacrificed, the
kidneys excised, homogenized and serial dilution was performed to measure
fungal burden. For each group, 4 mice were used. This experiment was
repeated four times with similar results. DC = Dendritic cells; Y = Yeast; H =
Hyphae. * P < 0.05 DC alone vs. experiment groups. ** P < 0.05 treated vs.
untreated DCs.

*

**

**

*

*

*

Figure 9. Secretion of cytokines from splenic cultures of mice vaccinated
with antigen pulsed pDCs. Spleens were excised from the mice systemically
challenged with C. albicans following adoptive transfer with pulsed pDCs. Yeast
and hyphal forms of C. albicans were used in 1:1 ratio to stimulate the
splenocytes. After 2h of incubation, 2.5 µg/ml of amphotericin B was added to
prevent Candida overgrowth followed by further incubation of 16 h. Cytokines in
the culture supernatants were analyzed by ELISA. * P < 0.05 DC alone vs.
experiment groups (pulsed with yeast or hyphae). ** P < 0.05 treated (pulsed with
PGEx/PGE2) vs. untreated DCs (pulsed with yeast or hyphae).
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To boost the immune response in vaccinated mice, a second adoptive
transfer was introduced followed by a systemic challenge. In mice vaccinated
with mDCs, yeast-pulsed, but not hyphae-pulsed DCs induced protective
responses against systemic infection (Figure 10). While there was a modest
decrease in kidney CFUs with yeast-pulsed DCs compared to unpulsed DCs,
exposure to PGE2 or PGE2 in the DC culture abrogated this effect. Interestingly,
mice receiving hyphae-pulsed DCs had increased fungal burden, which was
further exacerbated with prostaglandin treatment (Figure 8). This indicated that
along with exposure to PGE2, morphotype specific responses shift the outcome
of infection as reported previously [115].

Analysis of splenic Th1 and Th2

cytokines showed that mice receiving prostaglandin treated DCs produced less
IL-12 compared with untreated DCs (Figure 11). In addition there was a trend
towards increased IL-4 and IL-5 production with hyphae-pulsed DCs, which was
further increased with prostaglandin treatment (Figure 11).

There were no

significant differences with IFN-γ, TNF-α, IL-10, or TGF-β production (Figure 10
and data not shown). Immunohistochemistry analysis showed increases in PMN
staining in kidneys of groups that were not protected against systemic infection
(Figure 12a). There was also increased IL-4 and decreased IL-12 production in
prostaglandin treated or hyphae pulsed groups compared with the mice receiving
DCs pulsed with yeast (Figure 12b and d). Overall, however, there was
exacerbated Th17 cytokines in all groups of mice (Figure 12f and g).
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Figure 10. Assessment of protection from C. albicans infection following
double adoptive transfer with mDCs. Antigen pulsed mDCs were harvested
after 18h of stimulation. For vaccination, 5x105 cells were injected via the
intraperitonial route in 6-8 week old C57BL/6 mice on day 0 and day 7. Mice
were inoculated 7 d after the second vaccination by tail vein injection with C.
albicans strain SC5314 (2.5x105 CFU/mouse). After 7 days post-inoculation, the
mice were sacrificed, the kidneys excised, homogenized and serial dilution was
performed to measure fungal burden. For each group, 4 mice were used. This
experiment was repeated four times with similar results. DC = Dendritic cells
(plasmacytoid); Y = Yeast cells; H = Hyphae. * P < 0.05 DC alone vs.
experiment groups (pulsed with yeast or hyphae). ** P < 0.05 treated (pulsed with
PGEx/PGE2) vs. untreated DCs (pulsed with yeast or hyphae).
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Figure 11. Secretion of cytokines from splenic cultures of mice receiving
double vaccination with antigen pulsed mDCs. Spleens were excised from
the mice systemically challenged with C. albicans following two adoptive
transfers with pulsed pDCs. Yeast and hyphal forms of C. albicans were used in
1:1 ratio to stimulate the splenocytes. After 2h of incubation, 2.5 µg/ml of
amphotericin B was added to prevent Candida overgrowth followed by further
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incubation of 16 h. Cytokines in the culture supernatants were analyzed by
ELISA. * P < 0.05 DC alone vs. experiment groups (pulsed with yeast or
hyphae). ** P < 0.05 treated (pulsed with PGEx/PGE2) vs. untreated DCs (pulsed
with yeast or hyphae).
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Figure 10
continued.
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A) GrGr-1 (PMN marker)
DC

DC + Y

DC + Y + E2

Isotype Ctrl

DC + H

DC + H + E2

DC + Y

DC + Y + E2

DC + H

DC + H + E2

B) ILIL-12
DC

Isotype Ctrl

Figure 12. Immunohistochemistry analysis kidneys of mice receiving
double vaccination with antigen pulsed mDCs. Kidneys were excised from
mice systemically challenged with C. albicans following two adoptive transfers
with antigen pulsed pDCs. Tissues were fixed in 10% formalin and processed for
immunohistochemistry. 5µm sections were cut from paraffin-embedded kidney
tissue blocks. Antibodies used along with their respective companies purchased
from and the dilution used are listed in
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Table 2. For heat mediated antigen retrieval, sections were treated with for 20
min with 10mM sodium citrate buffer, 0.05% Tween 20, pH6.0. Incubation with
primary antibody was performed overnight at 4°C whereas incubation with the
biotin conjugated secondary antibody was performed for 30 min at room
temperature. To verify staining specificity, negative control slides or appropriate
isotype controls antibodies and at the same dilution as that of respective primary
monoclonal antibodies were used.
These isotype controls used were rat IgG,
IgM, IgG2b and IgG2a.
Samples were analyzed by light microscopy using
Olympus BX41 microscope and Qcolor3 software tool.
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Figure 12 Continued
C) IFNIFN-
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D) ILIL-4
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Figure 12 Continued

E) ILIL-10
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DC + Y + E2

Isotype Ctrl
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DC + Y
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Figure 12 Continued

G) ILIL-17
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DC + Y + E2

Isotype Ctrl
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DC + H
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H) ILIL-23
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More dramatic results were seen with double adoptive transfers with pDCs
in terms of protection.

Mice receiving yeast-pulsed pDCs showed a 3 log

decrease in fungal CFU in the kidneys at d 7 post-infection (Figure 13). Similar
to mDCs, addition of PGE2 or PGEx abrogated the ability of yeast-pulsed pDCs
to induce protection. Hyphae-pulsed pDC exacerbated infection and addition of
prostaglandins leads to increased fungal burden. IL-12 levels from restimulated
splenocytes correlated with fungal burden, with decreased levels observed in
mice that were not protected (Figure 14).

IL-4 and IL-5 levels were also

increased in mice vaccinated with hyphae pulsed pDCs. Interestingly, IL-6 and
TGF- levels were also increased in non-protected mice. While these cytokines
exert both pro- and anti-inflammatory effects, respectively, the combination of the
two has been shown to induce development of Th17 cells [180]. However, there
was no detectable IL-17 or IL-23 measured from splenocytes (data not shown).
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Figure 13. Assessment of protection from C. albicans infection following
double adoptive transfer with pDCs. Antigen pulsed pDCs were harvested
after 18h of stimulation. For vaccination, 5x105 cells were injected via the
intraperitonial route in 6-8 week old C57BL/6 mice on day 0 and day 7. Mice
were inoculated 7 d after the second vaccination by tail vein injection with C.
albicans strain SC5314 (2.5x105 CFU/mouse). After 7 days post-inoculation, the
mice were sacrificed, the kidneys excised, homogenized and serial dilution was
performed to measure fungal burden. For each group, 4 mice were used. This
experiment was repeated four times with similar results. DC = Dendritic cells
(plasmacytoid); Y = Yeast cells; H = Hyphae. * P < 0.05 DC alone vs.
experiment groups (pulsed with yeast or hyphae). ** P < 0.05 treated (pulsed with
PGEx/PGE2) vs. untreated DCs (pulsed with yeast or hyphae).
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Figure 14. Secretion of cytokines from splenic cultures of mice receiving
double vaccination with antigen pulsed pDCs. Spleens were excised from
mice systemically challenged with C. albicans following two adoptive transfers
with antigen pulsed pDCs. Yeast and hyphal forms of C. albicans were used in
1:1 ratio to stimulate the splenocytes. After 2h of incubation, 2.5 µg/ml of
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amphotericin B was added to prevent Candida overgrowth followed by further
incubation of 16 h. Cytokines in the culture supernatants were analyzed by
ELISA. * P < 0.05 DC alone vs. experiment groups (pulsed with yeast or
hyphae). ** P < 0.05 treated (pulsed with PGEx/PGE2) vs. untreated DCs (pulsed
with yeast or hyphae).

Figure 13
continued.
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Overall, protection was associated with increased Th1 and decreased Th2
cytokines in the spleen with pDCs.

However, the pattern of cytokines didn’t

completely match CFUs. We did not find any conclusive results with intracellular
cytokines staining from the spleen (data not shown). There are several studies
that suggest the cytokine responses associated with protection correlate with
local kidney responses as opposed to splenic responses [181, 182].

These

studies have depicted drastically increased expression of cytokine genes, various
innate immune regulation genes and genes correlated with the initiation of the
adaptive immune response. Therefore, kidney but not spleen cytokines were
analyzed by immunohistochemistry. Staining revealed increased PMN levels in
mice vaccinated with hyphae pulsed DCs, which was even more dramatic in DCs
that were treated with PGE2 (Figure 15a). This indicates a lack of resolution of
inflammation. Similar to splenic responses, IL-12 was most prevalent in mice
receiving yeast pulsed DCs (Figure 15b). There was dramatic IFN-γ staining in
kidneys of mice vaccinated with yeast pulsed DCs, but not in PGE2 treated or
hyphae pulsed DC groups (Figure 15c). Th2 cytokines IL-4 and IL-10 staining
correlated with a lack of protection, with the most staining observed with hyphae
+ PGE2 pulsed DCs (Figure 15d and e).

We also observed increased IL-6

production in non-protected groups, which has previously been associated with a
virulent infection (Figure 15f) [181]. Perhaps the most dramatic staining was
observed with Th17 cytokines, IL-17 and IL-23. While little to no kidney staining
was seen in mice vaccinated with yeast-pulsed DC, heavy staining was seen in
non-protected groups (Figure 15g and h). Overall, these data indicate that yeast
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pulsed DC induce a Th1 response, while PGE2 or hyphae shifts the response
towards a Th2 and over-exuberant local Th17 response.
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Figure 15. Immunohistochemistry analysis kidneys of mice receiving
double vaccination with antigen pulsed pDCs. Kidneys were excised from
mice systemically challenged with C. albicans following two adoptive transfers
with antigen pulsed pDCs. Tissues were fixed in 10% formalin and processed for
immunohistochemistry. Staining was visualized by light microscopy.
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Figure 16. Model for immunomodulation by Candida and PGE2 in (A)
Spleen and (B) Kidney.
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DISCUSSION

The early cytokine analysis with JAWSII cells revealed upregulation of Th2
cytokines IL-4, IL-10, and IL-13 in the presence of hyphae with PGE2. This is
consistent with the previous data reporting a bias towards non-protective Th2
cytokine responses in macrophages and monocytes in the presence of hyphae,
but not yeast [80]. However, the presence of PGE2 was required for robust Th2
cytokine production from DCs as was reported previously [183]. In addition, proinflammatory cytokines IL-6 and IL-15 were upregulated in the hyphae/PGE2
group. Although pro-inflammatory mediators are required for clearance of
Candida, this early inflammatory response also correlates with early expression
of SOCS-3, a suppressive cytokine, which is involved in promoting a Th2 (DC2)
phenotype [184]. We did not see any distinct dichotomy of Th1 versus Th2
response in the yeast versus hyphae treated group perhaps because of the early
time point (2h).

We also confirmed upregulation of IL-4, IL-6, and IL-10, and

down-regulation of IL-12 using qRT-PCR. With this analysis, there were more
obvious differences between the yeast and hyphae pulsed DCs, with greatest
responses observed with hyphae pulsed DCs treated with PGE2. Overall, this
indicates that PGE2 promotes a non-protective Th2 type response from DCs
(Figure 16).
In analyzing the effects of prostaglandins and antigenic stimulation on DC
maturation and activation, we compared cell surface marker expression in
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primary bone marrow derived mDCs and pDCs. Overall, the greatest increases in
CD86 expression occurred in DCs pulsed with hyphae in the presence of PGE2.
This indicates that DC activation is influence by both C. albicans morphotype and
PGE2. Interestingly, there was a more dramatic increase in CD86 with yeast
pulsed pDCs (3 fold) compared with mDCs (equivalent to control). This could be
one reason why we observed increased protection with yeast pulsed pDC
compared to mDCs during systemic Candida infection after DC vaccination. This
pattern is also reported in other studies where PGE2 were responsible for
upregulation of activation marker in the dendritic cells but in conjunction with a
cocktail of other compounds [185]. Analysis of early cytokine production by qRTPCR confirmed that both mDCs and pDCs behave similarly to the JAWSII cell
line. We observed increased IL-4, IL-6 and decreased IL-12 in hyphae pulsed
DCs in the presence of PGE2.

This confirms the utility of this cell line and

strengthens the argument that hyphae and PGE2 promote pro-Th2 responses in
DCs.
To examine effects of antigenic stimulation and prostaglandins on
subsequent responses in pDCs and mDCs, we analyzed cytokine production by
ELISA. We observed decreased Th1 cytokine production (IL-12 and IL-6) and
slightly increased Th2 cytokine production (IL-4) in the presence of fungal or host
PGE2. Studies have shown PGE2 to downregulate Th1 and increase Th2
responses, which is supportive of the results from our in vitro cytokine analysis
[183, 186, 187]. However, we also observed decreased IL-10 (Th2 and Treg),
and IL-23 (Th17). In addition, we did not observe any distinct dichotomy of Th1
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versus Th2 response in the yeast versus hyphae treated groups.

However,

PGE2 production was significantly increased in the hyphal pulsed DCs compares
with yeast pulsed. Because C. albicans was killed at the 2 h point, this PGE2
must be host-derived. Previous studies have shown induction of PGE2 synthesis
via activation of COX-2 transcription by C. albicans from various immune cells
like splenocytes, macrophages, and endothelial cells [161, 188, 189].

In

addition, there are evidences of PGE2 production from antigen presenting cells
during recurrent Candida vaginitis [190].
This difference in the pattern of PGE2 induction could be due to various
possibilities like differential PRR signaling or β-glucan contamination or perhaps
due to the differences in the concentration of manufacturer’s versus PGEx
generated in the lab. DCs recognize yeast and hyphal form of C. albicans via
TL4 and TLR2 receptors [80, 115, 116]. Also, studies have indicated that C.
albicans signaling via TLR2 pathway leads to the production of PGE2 from the
host and causes persistent type of infection [189]. This discrimination by the
DCs to interact via different TLRs could result from the fact that the hyphal cell
wall proteins are different from that of the yeast form of C. albicans.

The

presence of important adhesions like Als3 (Agglutinin like sequence) and Hwp1
(Hyphal wall protein), which are antigenic and play role in virulence caused by
this fungus has been associated with hyphal forms [191-193]. Prostaglandins
produced by both host and fungal cells also enhance morphogenesis in C.
albicans suggesting that eicosanoids could participate in modulating the immune
responses by both influencing Candida and DC biology in vivo [156, 162]. Thus,
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depending on the morphotypes of Candida (yeast or hyphal form), the DCs have
the ability to modulate the immune responses. Another factor contributing to the
differences in the cytokine responses induced from the bone marrow derived
dendritic cells after stimulation with PGE2

versus PGEx could be because of

the β-glucan contamination which is one of the main constituent of Candida cellwall polysaccharides [194]. Various studies have reported that β-glucan plays
active key role towards generating the immune responses by activating the
complement proteins and inducing array of inflammatory cytokines like TNF-α
and also leukotrienes from the host cells [195]. There is a possibility that PGEx
eluted from the anti-PGE2 column got this β-glucan contamination during washing
the anti-PGE2 column with buffers. Also, there could be differences in the PGE2
concentration from the manufacturer’s PGE2 with that of the PGEx which was
eluted from the anti- PGE2 column for which the concentration was determined
using the monoclonal ELISA kit.

All these factors might have possibily

contributed to the differences in the cytokine induction pattern after using these
compounds for dendritic cell stimulation assay.
To determine the downstream effects of antigenic stimulation in the
presence of PGE2, mice were vaccinated with DCs and challenged systemically.
After one round of vaccination, we observed protection only with pDCs pulsed
with yeast. This is in agreement with previous work by Zelante et al., which
showed that pDCs pulsed with yeast are able to generate protection compared to
mDCs [79]. However, after two rounds of vaccination, both yeast pulsed pDCs
and mDCs imparted protection compared to the hyphae pulsed group. This
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pattern of protective versus non-protective dichotomy with hyphae versus yeast
pulsed DCs has been documented in previous studies [80]. This could be due to
the fact that the hyphal but not yeast form of C. albicans was able to induce high
levels of PGE2 production from the DCs prior to adoptive transfer.
An important characteristic of prostaglandin activity is their potency at very
low (nanomolar) concentrations. In relation to this potency, most eicosanoids
have very short half-lives, being made de novo (as opposed to stored and
released) and acting near the site of their synthesis [134]. Addition of nanomolar
quantities of PGE2 to yeast-pulsed pDCs or mDCs abrogated their ability to
induce protection against systemic infection. The concentration of the PGE2 that
was used in our experiment were similar to that detected by the DCs at 18h time
point. To analyze the type of immune response generated after vaccination, we
measured re-stimulated splenocyte culture cytokine levels. With both pDCs and
mDCs, there was decreased IL-12 and increased IL-5 in groups that were not
protected after vaccination.

This indicates that protection correlates with

elaboration of a Th1 response. We also observed increases in IL-4 in mice
receiving hyphae pulsed DCs, which was further increased with prostaglandin
exposure. Interestingly, we also observed increased IL-6 and TGF- in nonprotected groups.

These cytokines are sufficient for the induction of IL-17 and

IL-17F expression in TCR-activated naïve CD4+ T cells [196].
The Th17 response also possibly plays a role in generating non-protective
response, however, this was more pronounced in the mice kidneys than spleen.
Our studies did not depict any recovery of fungal burden from other organs like
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mice liver, kidney or blood (data not shown). The findings from the
immunohistochemistry studies are also in alignment with the pattern of protection
observed in the mice after adoptive transfer. The kidneys from yeast pulsed
mice showed the production of protective Th1 cytokines (IFN-γ and IL-12)
compared to the other groups, which had more Th2 (IL-4) and pro-inflammatory
cytokine (IL-6) expression. The most dramatic staining was seen with Th17
cytokines (IL-17, IL-23) were very strong in the most of the groups except the
yeast pulsed pDCs indicating that Th17 pathway is associated with nonprotective responses and persistent fungal infection. Although we observed slight
protection with double adoptive transfer with mDCs pulsed with yeast, there was
dramatic Th17 cytokine staining in the kidneys.

It could be that there is a

threshold level of C. albicans fungal burden that initiates this dramatic response.
With pDCs, C. albicans was held to 102- 103 CFU/g tissue, while with mDCs,
levels reached 104.
Other work on C. albicans infections in the GI model have indicated that
both IL-23 and Th17 are induced in vaccinated mice and are non-protective,
resulting in defective fungal clearance by impairing the anti-fungal activities of
PMNs and prolonged inflammation [79]. However, in oral and systemic infection
models, IL-17 receptor A (IL-17RA) knockout mice are more susceptible to
infection in naïve animals, indicating that the Th17 pathway is necessary during
acute infections [108, 123]. Our studies indicate that in later stages of infection in
vaccinated mice, the Th17 response cytokines is associated with exacerbated
uncontrolled inflammation. Both IL-23 and IL-17 can inhibit neutrophil antifungal
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activity resulting in pathological form of inflammation associated with impaired
antifungal resistance [79]. Therefore, although neutrophils were recruited to the
kidneys, the antifungal activity is likely diminished, as indicated by the high fungal
burden. One of the mechanisms by which this could be verified in future studies
is by targeting the IL-17 pathway at different points of infection (early,
intermediate and late) with antibody-mediated IL-17 depletion in naïve vs.
immunized animals. Ours is the first study to report presence of Th17 cytokines
in the mice kidneys during systemic candidiasis is associated with a lack of
protection.
Our studies using DC vaccination allowed us to investigate downstream
effects of host and fungal prostaglandins on Candida-DC interactions.

Our

results indicate that the presence fungal PGE2 (PGEx) or PGE2 during the hostpathogen interaction with DCs can drive a non-protective response. This is
associated with generation of a non-protective Th2 response and repression of a
protective Th1 response.

Locally, we also observed exacerbated Th17

responses and uncontrolled fungal growth despite the presence of neutrophils at
the site of infection (Figure 16). This study indicates that local host or fungal
PGE2 production could shift responses in favor of the fungus, which is
detrimental during systemic infection. Therefore, fungal PGE2 production may be
considered a virulence factor. Understanding the interactions between PGE2 and
its effect on DCs is important towards developing potent therapeutic strategies to
treat Candida infection. This is especially important given the fact that Candida
infections are associated with high mortality rate and the antifungal agents like
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fluconazole, voriconazole, itraconazole etc. are associated with resistance
mechanisms [197-199]. In future, this study will also help towards understanding
the prostaglandin pathways and its downstream effects that can be extended
towards other pathogenic eukaryotic species.
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CHAPTER 2
Effect of PGEx and PGE2 on C. albicans uptake and
survival in macrophages
ABSTRACT
Macrophages play key roles in protecting against both mucosal and
systemic infections with the opportunistic fungal pathogen Candida albicans.
However, mechanisms controlling antifungal killing defenses of these phagocytes
are not well understood. C. albicans produces an immunomodulatory oxylipin
called PGEx, that is structurally and functionally similar to host PGE2. In addition,
it can produce authentic PGE2 from host arachidonic acid. To determine the
effects of fungal and host prostaglandins on interactions with macrophages, we
studied phagocytosis and intracellular survival, as well as production of reactive
oxygen and nitrogen species. Addition of PGE2 or PGEx inhibited phagocytosis,
while promoting intracellular survival of C. albicans in RAW264.7 cells. However,
increased survival was not accompanied by any reduction in nitric oxide or
peroxynitrite.

Therefore, the effects of these compounds may involve non-

oxidative mechanisms that require further investigation.
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INTRODUCTION

C. albicans is an opportunistic fungal pathogen that inhabits mucosal
surfaces including the oral cavity, gastrointestinal tract, and vagina [200]. Under
conditions that permit the outgrowth of Candida, mucosal colonization can lead to
infection and dissemination. Diseases range from superficial mucosal infections
to life-threatening systemic candidiasis. Risk factors for systemic infection include
immunocompromise, antibiotic therapy, and the use of indwelling medical
devices. Protective immune responses to candidal infection require both innate
and adaptive immunity. There is no evidence of complement or antibody
mediated clearance of C. albicans infection. Therefore, the first line of defense
against infection involves activated innate effector cells, including neutrophils and
macrophages.
Macrophages play an essential role during systemic candidiasis. During C.
albicans systemic infection, mice depleted of macrophages exhibit delayed
clearance and high kidney fungal burden [201]. Macrophages have direct
antimicrobial activity against such organisms and also promote antigen
presentation, polysaccharide sequestration, and production of cytokines and
chemokines. Mechanisms implemented by macrophages to combat infection
must involve killing C. albicans, both yeast and hyphal form. If C. albicans
survives intracellularly, macrophages could act as a vehicle to disseminate the
fungus to immunological privileged niches, which could result in escape from
innate and adaptive immune responses generated by the host [202]. There is
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also evidence that persistent infection is associated with the intracellular
residence of yeast cells in macrophages.
Macrophages can kill Candida via oxygen-dependent or independent
pathway [203]. Oxygen dependent pathways include production of both reactive
oxygen and nitrogen intermediates (ROI, RNI). In particular, nitric oxide (NO)
has strong antifungal activity; however, C. albicans can evade host defense by
suppression of NO/superoxide radical production by stimulated macrophages
[103-105]. Furthermore, what were thought to be two independent pathways, i.e.,
nitric oxide and superoxide anion, have now been shown to combine to form a
potent macrophage candidacidal molecule, peroxynitrite. Oxygen independent
pathways are less well studied. However, upon phagocytosis of C. albicans,
yeast forms can germinate and lyse macrophages [106]. Therefore, whether the
macrophage or the fungus prevails is dependent on several factors, including the
type of macrophage and activation state.
Activation of macrophages is influenced by the microenvironment as well
as the nature of the microbe or antigen. Whereas Th1 cytokines such as IFN
and TNF- stimulate antifungal activities, Th2 cytokines such as IL-10 are
inhibitory [204, 205]. C. albicans has also been shown to produce eicosanoids,
which are potent immune response regulators derived from arachidonic acid
(AA). C. albicans produces a compound that cross-reacts with antibodies to host
prostaglandin E2 (PGE2), called PGEx.

In the presence of host AA, PGEx

production is significantly upregulated, indicating that C. albicans can produce
PGE2 from host lipid precursors.

Mass spectrometry analysis revealed that
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PGEx derived from AA is structurally identical to PGE2 [154]. Overall, 99.9% of
AA-derived PGEx is PGE2.

In terms of macrophages, PGE2 can inhibit

phagocytosis and intracellular killing of bacteria [206, 207].

However, other

reports have indicated that PGE2 is crucial for phagocyte killing of parasites, via
induction of nitric oxide [208]. In the present study, we tested the effect of fungal
PGE2 (PGEx) and host PGE2 on Candida phagocytosis and survival in
macrophage cell line, RAW264.7 and how these compounds influence oxidative
killing mechanisms.
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MATERIALS AND METHODS

Cell culture. The macrophage cell line RAW264.7 (originally from ATCC TIB
67) was kind gift from Dr. M. Neely (Wayne State University, Detroit, MI). Cells
were cultured in Dulbecco’s modified eagle’s medium (DMEM) supplemented
with 10% heat inactivated fetal bovine serum, 25mM HEPES, 2 mM Glutamine,
100 IU penicillin/ml and 100µg streptomycin/ml (D-10 medium) and incubated at
37°C, 5% CO2 with 95% humidity.

For experiments, cells were seeded in

100 cm2 T75 flask at the density of 1.5 X105 cells /ml.

C. albicans Strains and Culture Conditions. The C. albicans strain SC5314
used in this study is a prototrophic parental strain [168]. This strain was
subcultured from frozen stocks and grown overnight at 30°C in Sabouraud
dextrose agar (SDA) (Becton, Dickinson and Company, Sparks, MD). For the
liquid cultures, isolated colonies from the SDA plates were inoculated into
Sabouraud dextrose broth (SDB) with constant shaking.

Isolation of fungal PGEx. C. albicans strain SC5314 was grown overnight at
37C in 10 ml RPMI containing 100 mM arachidonic acid. Culture supernatants
were loaded onto a PGE2 affinity column (Caymen Chemical), washed, and
eluted according to manufacturers instructions. The eluates were dried under a
stream of nitrogen gas and resuspended in 500 µl PBS. PGEx concentrations
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(approximately 20ng) determined using a PGE2 monoclonal ELISA (Cayman
Chemical, Ann Arbor).

Phagocytosis assay. Overnight C. albicans cultures were washed 2-3 times
with 10% DMEM at 4°C by centrifuging at 4000 xg. Sonication was performed at
the highest setting for 10 min followed by keeping it on the ice for 30 min to
obtain single cell suspensions. Macrophages were infected with C. albicans at
an MOI of 5 in the presence or absence of PGE2 or PGEx at a final concentration
of 2nM. After 15min or 3h of incubation, the supernatant was removed and the
cells were washed three times with 1ml sterile 1x PBS to remove non-adherent
organisms. To obtain phagocytosed yeast, macrophages were lysed with sterile
water. The recovered yeast cells, from the supernatant fraction as well as after
lysis, were plated on SDA media after serial dilution.

The formula used for

calculations:
% phagocytosis = 1 – [CFU t(initial)/intracellular CFU t(15 min)] X 100
% Intracellular killing = 1 – [intracellular CFU t(15 min)/intracellular CFU t(3 h)] X
100

Fluorescence microscopy.

For monitoring phagocytosis in macrophages,

RAW264.7 cells seeded on coverslips at a concentration of 106 cells/ml. C.
albicans was stained with 1µl calcufluor at a concentration of 1mg/ml (Fluka,
Seelze, Germany) for 10 min at 1x106 yeast cells per 200 µl and added to
macrophages at an MOI of 5. To monitor phagocytosis after 15 min incubation,
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the supernatant was washed and staining of extracellular non-phagocytosed
yeast

was

quenched

with

trypan

blue.

Cells

were

fixed

with

4%

paraformaldehyde (in PBS) at 4°C for 10min. To monitor intracellular survival at
3 h, cells were incubated as previously mentioned but Candida was pre-stained
with FUN-1 fungal viability stain according the manufacturer’s instructions
(Invitrogen). FUN-1 distinguishes live (red) versus dead (green/yellow) yeast.
For fluorescence microscopy, a Nikon Eclipse E800 and Metamorph software
was used.

Growth curve. C. albicans was grown overnight in SD broth while shaking at
30C. The culture was washed, counted, and diluted into 10 ml fresh SD broth at
a final concentration of 105/ml. PGEx or PGE2 was added to a final concentration
of 2nM and culture were incubated at 30°C with shaking. The absorbance was
measured at 600nm at various time points up to 48h. For the blank (control)
sample, only SDB without yeast was used. CFU analysis was performed by
serial dilution of the cultures at various time points and plating onto SD agar
plates.

Nitrite Assay. RAW264.7 cells were plated at a concentration of 5x105 cells/ml
in 24-well plates and grown for 24 h with or without L-NMMA (competitive NOS
inhibitor) at final concentration of 500µM 24 h prior to infection. Cells were
stimulated with LPS (1µg/ml final concentration) and infected with C. albicans at
MOI 10:1. Cells were incubated at 37°C, 5% CO2 for 3h. Both PGEx and PGE2
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were used at a final concentration of 2nM. The 24-well plate was centrifuged at
1000 rpm for 10 min and nitrite levels in cell supernatants were assayed using a
Griess reagent kit (Molecular Probes) according to the manufacturer’s
instructions.

Peroxynitrite Assay. RAW264.7 cells were plated at a concentration of 5x105
cells/ml in 24-well plates and grown for 24 h. Cells were washed and stimulated
with LPS (1µg/ml final concentration) and infected with C. albicans at MOI 10:1
for 3h. Both PGEx and PGE2 were used at a final concentration of 2nM. Control
cells were stimulated with zymosan (200µg/ml final concentration). Cells were
incubated at 37°C, 5% CO2 for 3h. The plate was centrifuged 1000 rpm for 10
min and peroxynitrite levels in cell supernatants were assayed using a
peroxynitrite detection kit (Cell Technology Inc.) according to the manufacturer’s
instructions.

Statistical analysis. The Student’s t test (two-tailed, unequal variance) was
used to analyze the significance of differences between two experimental groups.
Significance was considered with a P < 0.05 or less. The data recorded are
representative of either two or three independent experiments.
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RESULTS

To study the effect of prostaglandin (PGEx and PGE2) on macrophage
phagocytosis of C. albicans, viable intracellular yeast were monitored 15 min
after infection. The data showed a decrease in percentage of phagocytosis in
the prostaglandin treated groups. Phagocytosis decreased by about 20% in the
PGEx treated group, whereas in the PGE2 treated group, percent phagocytosis
was reduced by about 10% (Figure 17).
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Figure 17. Effect of PGE2 and PGEx on macrophage phagocytosis of C.
albicans. C. albicans strain SC5314 was grown overnight in SD broth at 30°C.
Cultures were washed with D-10 medium followed by sonication to create a
single cell suspension. RAW264.7 cells were infected at an MOI of 5 in the
presence or absence of PGE2 or PGEx at a final concentration of 2nM. After 15
min, supernatant was removed and cells were washed three times with sterile 1X
PBS. Cells were lysed with sterile water and both supernatants and lysates were
diluted and plated onto SD plates to determine CFU. The experiment was
repeated 4 times in triplicate.
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To determine if prostaglandins influence subsequent intracellular survival
viable yeast were monitored 3 h post-infection. We observed a modest increase
in intracellular survival in the macrophages treated with PGE2 (Figure 18).
However, there was a significant increase in intracellular survival with
macrophages treated with PGEx compared to the control group (Figure 18). To
further verify the increase in phagocytosis, we performed fluorescence
microscopy. C. albicans was labeled with calcofluor white and used to infect
macrophages seeded onto cover slips. We observed an increase in the number
of intracellular yeast in the presence of PGE2 or PGEx compared to the control
group (Figure 19). Staining of C. albicans with FUN-1 also showed increased
viable yeast in prostaglandin treated macrophages, particularly with PGEx
(Figure 20). To rule out the possibility that prostaglandin was directly contributing
to the growth or budding of C. albicans, we performed growth curve assays. C.
albicans was incubated in the presence of PGE2 or PGEx and growth was
monitored over 48 h. We observed no increases in presence of prostaglandin at
early or late time points (Figure 21).
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Figure 18. Effect of PGE2 and PGEx on intracellular survival of C. albicans
in macrophages. C. albicans strain SC5314 was grown overnight in SD broth at
30°C. Cultures were washed with D-10 medium followed by sonication to create
a single cell suspension. RAW264.7 cells were infected at an MOI of 5 in the
presence or absence of PGE2 or PGEx at a final concentration of 2nM. PGEx
was obtained by passing the overnight cultured Candia supernatant
supplemented with 100mM arachidonic acid through anti-PGE2 column. PGE2
was commercial standard prostaglandin obtained from Cayman chemicals, Ann
Arbor. After 15 min, supernatant was removed and cells were washed three
times with sterile 1X PBS. Cells were lysed with sterile water and both
supernatants and lysates were diluted and plated onto SD plates to determine
CFU. The experiment was repeated 4 times in triplicate. Experiments were
repeated 3 times with 3 replicates each. * P < 0.05 control vs. experiment group.
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Untreated

2 nM PGE2

2 nM PGEx

Figure 19. Effect of PGE2 and PGEx on C. albicans phagoctysosis by
immunofluorescence microscopy. C. albicans strain SC5314 was grown
overnight in SD broth at 30°C. Cultures were washed with D-10 medium
followed by sonication to create a single cell suspension. Yeast were stained with
calcofluor white prior to infection. RAW264.7 cells were seeded onto cover slips
and infected at an MOI of 5 in the presence or absence of PGE2 or PGEx at a
final concentration of 2nM. After 3h incubation, the supernatant was washed and
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quenched with trypan blue to destain the non-phagocytosed yeast. Cells were
fixed with 4% paraformaldehyde and analyzed by fluorescence microscopy using
a Nikon Eclipse E800 with Metamorph software. Data is representative of three
independent repeats.
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Figure 20. Effect of PGE2 and PGEx on C. albicans intracellular viability. C.
albicans strain SC5314 was grown overnight in SD broth at 30°C. Cultures were
washed with D-10 medium followed by sonication to create a single cell
suspension. Yeast were stained with FUN1 prior to infection, which distinguishes
live (red) from dead (green-yellow) fungi. RAW264.7 cells were seeded onto
cover slips and infected at an MOI of 5 in the presence or absence of PGE2 or
PGEx at a final concentration of 2nM. After 3 h incubation, the cells were
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washed and analyzed by fluorescence microscopy using a Nikon Eclipse E800
with Metamorph software. Data is representative of three independent repeats.
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Figure 21. Effect of PGE2 and PGEx on C. albicans growth in vitro. C.
albicans was grown overnight in SD broth while shaking at 30C. The culture
was washed, counted, and diluted into 10 ml fresh SD broth at a final
concentration of 105/ml. PGEx was obtained by passing the overnight cultured
Candia supernatant supplemented with 100mM arachidonic acid through antiPGE2 column. PGE2 was obtained as commercial standard prostaglandin from
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Cayman chemicals, Ann Arbor. PGE2 and PGEx was added to a final
concentration of 2nM and culture were incubated at 30°C with shaking. A) The
absorbance was measured at 600nm at various time points up to 48h. For the
blank (control) sample, only SDB without yeast was used. B) CFU analysis was
performed by serial dilution of the cultures at various time points and plating onto
SD agar plates. Data is representative of three indepdendent experiements
assayed in duplicate.
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While macrophages possess both oxygen dependent and independent
antimicrobial defenses, it has been suggested that the oxidative burst is the
major antifungal defense. This is due to the fact that yeast germinate with
macrophages, which leads to cell lysis.

Both reactive oxygen and nitrogen

species (ROI/RNI) production contribute to the candidicidal activity of
macrophages, with nitric oxide and peroxynitrite exhibiting the strongest
antifungal activity [205, 209]. We tested the effect of prostaglandins on inhibiting
nitrite and peroxynitrite during infection with C. albicans. Macrophages were pretreated with or without L-NMMA, a competitive iNOS inhibitor, 24 h prior to
infection. The results showed a trend in the decrease of nitrite production in
each group, which was associated with a slight increase in fungal burden (Figure
22). However, in the PGEx treated macrophages, L-NMMA treatment had no
effect on fungal survival. This indicates that the effect of PGEx on increasing
intracellular survival is not due to repression of iNOS and nitric oxide production.
There were also no significant differences in peroxynitrite production in the
presence of PGE2 or PGEx (Figure 23). Therefore, prostaglandins must work to
increase intracellular survival by influencing other antifungal pathways.
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Figure 22. Effect of PGE2 and PGEx on NO production by macrophages.
RAW264.7 cells were seeded overnight in 24-well plate with or without L-NMMA
(competitive NOS inhibitor) at final concentration of 500µM 24 h prior to infection.
Cells were stimulated with LPS (1µg/ml final concentration) and infected with C.
albicans at MOI 10:1 for 3h. Both PGEx and PGE2 were used at a final
concentration of 2nM. The 24-well plate was centrifuged at 1000 rpm for 10 min
and nitrite levels in cell supernatants were assayed using a Griess reagent kit
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(Molecular Probes) according to the manufacturer’s instructions. Data is
representative of three independent repeats performed in triplicate. * P < 0.05
control vs. experimental group.
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Figure 23. Effect of PGE2 and PGEx on NO production by macrophages.
AW264.7 cells were plated at a concentration of 5x105 cells/ml in 24-well plates
and grown for 24 h. Cells were washed and stimulated with LPS (1µg/ml final
concentration) and infected with C. albicans at MOI 10:1 for 3h. Both PGEx and
PGE2 were used at a final concentration of 2nM. Control cells were stimulated
with zymosan (200µg/ml final concentration). Cells were incubated at 37°C, 5%
CO2 for 3h. The plate was centrifuged 1000 rpm for 10 min and peroxynitrite
levels in cell supernatants were assayed using a peroxynitrite detection kit
according to the manufacturer’s instructions. Data is representative of three
independent repeats performed in triplicate.

115
DISCUSSION

Macrophages are potent antifungal effector cells that are required for
defense against both mucosal and systemic infections with C. albicans [201,
210]. Macrophages have the ability to kill both yeast and hyphal forms of C.
albicans.

However, intracellular killing is restricted to the yeast form, as the

hyphal form is not phagocytosed, presumably due to the large size [211].
Intracellular killing is particularly important, as survival within the macrophage
could lead to dissemination using the host cell as a vehicle to evade other
immune effector responses.

Therefore, interactions that govern intracellular

survival are of interest in terms of controlling infection. C. albicans produces a
PGE2 cross reactive compound called PGEx from endogenous lipid precursors
that behaves like host PGE2. Because PGEx works similar to PGE2, it is likely
that the ring group which is recognized by EP receptors is similar, but the overall
carbon length in shorter.

In addition, in the presence of arachidonic acid,

Candida produces copious amounts of authentic PGE2. Approximately 99.9% of
the PGEx derived from arachidonic acid is PGE2. We therefore tested the effects
of commercially available PGE2 and fungal PGEx (99.9% PGE2) on influencing
macrophage antifungal activity.
Our data shows that PGEx and PGE2 can decrease phagocytosis and
increase intracellular survival of C. albicans within macrophages. Interestingly,
these results were more dramatic with PGEx, compared with PGE2. Firstly, the
percentage of phagocytosis decreased by about 20% in the PGEx treated
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groups, whereas in the PGE2 treated group, percent phagocytosis came down by
about 10% (Figure 1). Secondly, we observed an increase in the intracellular
survival of C. albicans inside the macrophages by about 10% in the PGE2 treated
group and approximately by 60% in the PGEx treated group compared to the
control (Figure 2). This was further verified with our fluorescence microscopy
data (Figure 3 and Figure 4). These experiments confirmed that host PGE2 and
fungal PGEx aid in overcoming antifungal defenses of macrophages. The fact
that PGEx produced a more potent response may be due to effects of the
endogenous PGE2 cross-reactive compound that is co-isolated with fungal PGE2.
In addition, this may be due to slight variations in the concentration of PGEx.
Concentrations of PGEx were determined by ELISA, while the commercially
available PGE2 was determined by analytical methods by the manufacturer.
The effect of PGE2 and PGEx on increasing intracellular survival did not appear
to be due to the direct effect of prostaglandins on C. albicans growth. This is
based upon our observation from the growth curve study over a period of 48h
(Figure 5). There was no change in the density of C. albicans in presence of
prostaglandins compared to untreated cells. C. albicans can use arachidonic
acid as a sole carbon source, which is structurally very similar to PGE2 [212].
However, levels of this fatty acid that promote growth are much higher than those
used in our assays (micromolecular vs. nanomolecular). Therefore, it is unlikely
that prostaglandin treatment was used as a nutrient by C. albicans during
macrophage infection. This data implies that there is perhaps some other
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uncharacterized mechanism implemented by prostaglandins that aids in the
intracellular survival of C. albicans inside RAW264.7 cells.
Preliminary advances have been made in our understanding of how C.
albicans interacts with RAW264.7 cells in presence of prostaglandins, but large
gaps in our knowledge still remains to verify the underlying mechanism.
Macrophages employ several candidacidal mechanism to eliminate C. albicans
[202]. Treatment with PGE2 or PGEx resulted in increased intracellular survival,
which may be due to effects on one specific or combination of various
candidacidal mechanisms such as suppression of reactive oxygen, nitrogen
intermediates, alteration of trafficking or pH. Previous studies have depicted that
hyphal form but not yeast form are susceptible to extracellular antifungal
mechanisms employed by macrophages, which likely involves reactive oxidative
products [211]. Therefore, it is assumed that the yeast form must be eliminated
by phagocytosis and intracellular killing methods.
Both reactive oxygen and nitrogen species (ROI/RNI) production
contribute to the candidicidal activity of macrophages, with nitric oxide and
peroxynitrite exhibiting the strongest antifungal activity [205, 209]. In addition, a
complex “cross-regulation” takes place between the COX and NO pathways. It
has been reported that PGE2 can either activate or inhibit NO production
depending on the microenvironment NO [213, 214], in part derived from iNOS,
negatively regulates the immediate-early induction of COX-2 in response to
inflammatory stimuli [215]. Therefore, we examined the effect of host and fungal
prostaglandins on RNI production by macrophages. Our data indicate that a nitric
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oxide synthase inhibitor slightly reduced NO production from macrophages,
which resulted in increased fungal burden in control and PGE2 treated groups.
However, with PGEx treated groups, we observed no increase in fungal burden
in the presence of the inhibitor. This may be due to the fact that fungal burden
was already maximal with PGE2 treatment. However, neither PGE2 nor PGEx
alone inhibited nitric oxide or peroxynitrite production; therefore, this is not the
mechanism of action of these compounds.
Another main antimicrobial mechanism employed by macrophages is
intracellular killing by phagolysosomal fusion, which results in a reduction in pH
and activation of degradative enzymes. It has been reported that phagocytosed
yeast traffic to late endosomes and fuse with lysosomes [216]. This is followed
by germination into hyphae, which distends the host cell membranes, resulting in
escape from the macrophage. Germination was found to be dependent on the
reduction in pH associated with phagolysosomal fusion. Hyphae, which are not
phagocytosed, can penetrate macrophages and also acquire lysosomal markers
on the surface of the endosome.

This indicates that internalization and

phagolysosomal fusion C. albicans favors intracellular survival and potentially
virulence [216]. Keeping that in mind, it would be worthwhile to study the effects
of PGEx and PGE2 on changes in phagolysososmal fusion and pH during C.
albicans infection.
In summary, our results suggest that host PGE2 and fungal PGEx can
influence fungal survival during interaction of C. albicans with macrophages.

In

terms of fungal infection, production of prostaglandin by either the host or the
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fungus may influence the outcome of the interaction. However, fungal PGEx is
more potent than host PGE2 overall. Intracellularly, this compound may exert a
more directed response, inhibiting antifungal effector activity within the target cell.
Therefore, development of drugs that specifically inhibit fungal prostaglandin
production is warranted.
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CHAPTER 3
Role of Eicosanoids in Defense Against Mucosal and
Systemic Candidiasis
ABSTRACT
Candida

albicans

produces

both

endogenous

prostaglandin-like

compounds as well as authentic prostaglandins (PGE2) from host arachidonic
acid. Prostaglandin production is highest in the hyphal or biofilm form of C.
albicans, which are both associated with increased virulence or ability to cause
infection. Synthesis of fungal prostaglandins can be inhibited in vitro with
eicosanoid inhibitors. In addition, these inhibitors can interfere with C. albicans
germination and biofilm formation.

Therefore, we tested whether eicosanoid

inhibitors can affect the outcome of either mucosal infection (vaginitis) or
systemic infection (intravenous route) in mice. We compared the effects of a
traditional antifungal drug, amphotericin B, with two eicosanoid inhibitors that had
been previously shown to inhibit C. albicans eicosanoid production in vitro
(NDGA and indomethacin). NDGA is a plant polyphenol and inhibits both COX
and lipoxygenase (LO), while indomethacin is a non-selective COX inhibitor. In
both types of infections, NDGA treatment resulted in decreased fungal burden.
This correlated with decreased PGE2 levels in the host, as well as alterations in
cytokine expression. Therefore, eicosanoid inhibitors may useful in combination
with conventional antifungal agents in treating fungal infections.
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INTRODUCTION

Mucosal and systemic infections caused by C. albicans pose a significant
clinical threat to the immunocompromised and immunocompetent population [2,
3].

Various persistent forms of infections such as recurrent vaginitis, are

associated with increased C. albicans colonization and are associated with
increased PGE2 levels locally [217]. Previous studies have demonstrated the
production of PGE2 from both C. albicans and host cells, although, the
understanding of their role towards pathogenesis and persistence is still at
nascent stage. Thus prostaglandins might have some key role to play towards
promoting fungal virulence. Therefore, it is important to study the effect of this
compound in C. albicans colonization, infection, and modulation of immunity.
Prostaglandins are pleiotropic molecules that regulate a variety of
physiological processes including modulation of immune response [218]. They
can elicit both pro- and anti-inflammatory responses.

In terms of innate

immunity, PGE2 can inhibit macrophage phagocytosis and activation and
influence dendritic cell maturation and cytokine production. In terms of adaptive
immunity, PGE2 has also shown to be able to inhibit Th1 type of adaptive
immune response and promote Th2 type of responses, the later being associated
with non-protective immune response to C. albicans infection [219-222].
Prostaglandins can be produced by both Candida and the host cells [156, 160,
223]. In mammalian cells, prostaglandins are produced from the arachidonic
acid precursor by the action of cyclooxygenase (COX) enzymes, both COX-1 and
COX-2.

COX-1 is constitutively expressed for steady state production of
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eicosanoids, whereas COX-2 is an inducible form associated with immune
responses [224]. Previous in vitro studies have demonstrated that C. albicans
induces PGE2 production from host cells via the COX-2 pathway [161].
Precursors of C. albicans oxylipins can also be used by COX-2 to produce array
of other lipid compounds.

This emphasizes the presence of transcellular

host/fungal eicosanoid pathway [225].

Studies by Douglas et al. have depicted

that nonsteroidal anti-inflammatory drugs (NSAIDS), which are cyclooxygenase
inhibitors, had inhibitory effects on C. albicans germination and biofilm formation,
activities associated with infection and virulence [226]. These drugs have the
capacity to inhibit the prostaglandin formation from host cells by inhibiting the
action of the enzyme(s) COX-1 or COX-2 or both [224]. To this end, in this study
we examined the role of host eicosanoids in both mucosal (vaginitis) and
systemic infection models through administration of prostaglandin inhibitors.
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MATERIALS AND METHODS

Mice. Female retired breeders or 6-8 week old mice of C57BL/6 strain were
obtained from Charles River Laboratories (Wilmington, MA). All mice were
maintained at an American Association for the Accreditation of Laboratory Animal
Care-accredited animal facility at Wayne State University (WSU) and housed in a
pathogen-free environment in accordance with the procedures outlined in the
Guide for the Care and Use of Laboratory Animals under an animal study
proposal approved by the WSU animal investigation committee.

C. albicans Strains and Culture Conditions. The C. albicans strain SC5314
used in this study is a prototrophic parental strain [168]. This strain was
subcultured from frozen stocks and grown overnight at 30°C in Sabouraud
dextrose agar (SDA) (Becton, Dickinson and Company, Sparks, MD). For liquid
cultures, isolated colonies from the SDA plates were cultured in Sabouraud
dextrose broth (SDB) with constant shaking. To obtain hyphal form, yeast form
of C. albicans was added to RPMI supplemented with 10% FBS at the
concentration of 1 x 106 Candida per ml of media. Hyphae were generated after
2 h incubation at 37°C.

Vaginal infection model. Three days prior to inoculation, mice were
subcutaneously injected with 0.01 mg/mouse of 17estradiol valerate (Sigma)
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dissolved in sesame oil. This was followed with estrogen administration at every
one week interval [43]. The control groups of mice received estrogen treatment
and were mock inoculated with PBS.

On day 0, mice were inoculated

intravaginally with 5x106 C. albicans in 30µl PBS using a pipette. On day 2, mice
were

administered

amphotericin

B

or

eicosanoid

inhibitors

(NDGA,

indoemethacin) vaginally at the concentration of 25 mg/kg. After 6 days of drug
administration, the mice were euthanized on day 7 and the CFU were recovered
after lavaging vaginal tissues twice with sterile PBS (each wash 50µl).

The

vaginal fungal burden was analyzed by performing serial dilutions of vaginal
lavage samples and plating them on SDA plates.

Vaginal Homogenates. For cytokine analysis in the vaginitis model, vaginal
tissue was excised and homogenized in 1ml of buffer containing PBS, 0.05%
Triton X-100, and protease inhibitor.

This volume was further centrifuged at

800g for 5 min to remove the cellular debris and the clear supernatant was
collected for cytokine analysis. Previous studies have demonstrated that
presence or absence of homogenized tissue does not interfere with the levels of
endogenous cytokines following the homogenization process [43].

Systemic infection model. Mice were challenged by intravenous tail injection
with C. albicans at the concentration of 2.5 X 105 CFU/mouse in 250 µl of sterile
PBS using a 30-gauge needle attached to a 1-ml syringe. The mice challenged
with C. albicans were treated with amphotericin B (amphotericin B) or eicosanoid
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inhibitors

(nordihydroguaretic

acid/NDGA),

indomethacin)

at

different

concentrations (5, 10, 25 mg/kg) subcutaneously daily for 6 post-infection. On
day 7, the kidneys were harvested for CFU analysis and the spleens for cytokine
analysis.

CFU Assay. To determine the amount of fungal growth in the organs of the
mice, the kidney and the liver were weighed and homogenized using a tissue
tearor.

Serial dilutions of tissue homogenates were made in sterile water and

were plated onto SD agar to determine the CFU per gram per organ in each
group of mice.

Splenocyte cultures.

For the analysis of cytokines induces in the systemic

model, spleens were excised from the C. albicans infected mice and the
splenocytes were isolated from them. A 1:1 ratio of both yeast and hyphal forms
of C. albicans were used at MOI 1:2 to stimulate the splenocytes. After 2 h of
incubation, 2.5 µg/ml of amphotericin B was added to prevent Candida
overgrowth followed by further incubation of 16 h at 37°C, 5% CO2 incubator.
The supernatants were collected and the levels of cytokines were measured by
ELISA.

Splenocyte Harvest and Pulsing. Spleens were excised from the C. albicans
infected mice and the splenocytes were isolated from them. A 1:1 ratio of both
yeast and hyphal forms of C. albicans were used at MOI 1:2 to stimulate the
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splenocytes. After 2 h of incubation, 2.5 µg/ml of amphotericin B was added to
prevent Candida overgrowth followed by further incubation of 16 h at 37°C, 5%
CO2 incubator.

The supernatants were collected and the levels of cytokines

were measured by ELISA.

Enzyme Linked Immunosorbent Assay. Cell culture supernatants (DCs and
splenocyotes) were analyzed for the following cytokines by ELISA: IL-4, IL-5, IL6, IL-10, IL-12, IL-13, IFN-γ, TGF-β, TNF-α, and IL-23.

The detection limits

(pg/ml) for the assays were <3.90 for IL-4, < 3.90 for IL-5, <3.90 for IL-6, <
31.25 for IL-10, <15.62 for IL-12, <3.90 for IL-13, < 15.62 for IFN-γ, <62.5 for
TGF-β, <7.81 for TNF-α and <7.81 for IL-23 (eBioscience). In addition, vaginal
lavages and serum samples were also tested to analyze the levels of PGE2
(Cayman chemicals). The absorbance of the plates was measured at 450nm
using Multiskan Ex microplate reader (Thermo Electron Corporation) and
analyzed with Ascent Software.

Statistical Analysis. The Student’s t test (two-tailed, unequal variance) was
used to analyze the significance of differences between two experimental groups.
Significance was considered with a P < 0.05 or less. The data recorded are
representative of either two or three independent experiments.
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RESULTS

To investigate the effects of eicosanoid inhibitors on the course of
mucosal candidiasis, we inoculated the estrogenized mice vaginally with C.
albicans. We compared the effects of a traditional antifungal drug, amphotericin
B, with two eicosanoid inhibitors that had been previously shown to inhibit C.
albicans eicosanoid production in vitro (NDGA and indomethacin) [154]. NDGA
is a plant polyphenol and inhibits both COX and lipoxygenase (LO), while
indomethacin is a non-selective COX inhibitor. The drugs were administered
vaginally daily from day 2 to day 7 at a concentration of 25 mg/kg.

This

concentration was chosen based on previous studies using topical or oral
administration [227-229]. On day 8, the mice were sacrificed and their vaginal
fungal burden and induced cytokine levels from the vagina were evaluated. As
expected, local amphotericin B treatment reduced vaginal fungal burden by
approximately 2 logs (Figure 24). Surprisingly, treatment with NDGA was more
effective than amphotericin B at reducing C. albicans growth, with approximately
3 logs reduction. However, treatment with indomethacin had no significant effect
on fungal burden.
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Figure 24. Effect of eicosanoid inhibitors or antifungal drugs on C.
albicans burden in experimental vaginitis. On day 0, estrogenized mice were
inoculated vaginally with 5X106 candida per 10µl PBS. On day 2, eicosanoid
inhibitors (NDGA, Indomethacin) or antifungal drugs (amphotericin B) were
administered vaginally at the concentration of 25 mg/kg/mice. After 6 days of
drug administration, the mice were euthanised on day 7 and the CFU were
recovered after lavaging vaginal tissues twice with sterile PBS (each wash 50µl)
followed by serial dilution and plating on SDA plates. Results are representative
of three independent repeats. * P < 0.05 treated vs. untreated group.

129

To examine effects of drug treatment on vaginal immune mediator
production, PGE2 levels were analyzed in vaginal lavage samples. Compared
with uninfected mice, vaginal tissues from mice infected with C. albicans showed
induction of significant levels of PGE2 (Figure 25). Treatment with amphotericin B
resulted in a reduction in PGE2 levels, which could be attributable to reduced
fungal burden. Treatment with NDGA had the most significant effect on reducing
PGE2 levels, lowering to approximately 100 pg/ml. Interestingly, indomethacin
treated mice showed the induction of highest concentration of PGE2 induction,
indicating this drug had no effect on inhibiting eicosanoid production.

130

**
*

**

**

Figure 25. Effect of eicosanoid inhibitors or antifungal drugs on vaginal
PGE2 levels during experimental vaginitis. On day 0, estrogenized mice were
inoculated vaginally with 5X106 candida per 10µl PBS. On day 2, eicosanoid
inhibitors (NDGA, Indomethacin) or antifungal drugs (amphotericin B) diluted in
10µl of DMSO were administered vaginally at the concentration of 25
mg/kg/mice. After 6 days of drug administration, the mice were euthanised on
day 8 and the vaginal tissues were lavaged twice with sterile PBS (each wash
50ul). This homogenized tissue was centrifuged and the supernatant was used
to measure PGE2 levels by ELISA. Results are representative of three
independent repeats. * P < 0.05 infected vs. uninfected group. ** P < 0.05 treated
vs. untreated group.
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We next analyzed local cytokines responses in vaginal homogenates. We
observed a reduction in pro-inflammatory cytokine IFN-γ in infection mice
compared with uninfected mice; however, overall levels of this cytokine are
relatively low (Figure 26).
production.

Treatment with NDGA partially restored IFN-

Infected mice also showed reduced IL-10, which can promote

tolerogenic responses at mucosal surfaces. Treatment with NDGA partially
restored IL-10 levels. No significant levels of IL-4 or TGF- were detected in
vaginal homogenates.
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Figure 26. Effect of eicosanoid inhibitors or antifungal drugs on vaginal
cytokine levels during experimental vaginitis. On day 0, estrogenized mice
were inoculated vaginally with 5X106 candida per 10µl PBS. On day 2,
eicosanoid inhibitors (NDGA, Indomethacin) or antifungal drugs (amphotericin B)
diluted in 10µl of DMSO were administered vaginally at the concentration of 25
mg/kg/mice. After 6 days of drug administration, the mice were euthanised on
day 8 and the vagina was excised and homogenized in 1ml sterile buffer
containing PBS, 0.05% Triton X-100, and protease inhibitor. This homogenized
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tissue was centrifuged and the supernatant was used to measure cytokine levels
by ELISA. Results are representative of three independent repeats. * P < 0.05
treated vs. untreated group. ** P < 0.05 treated vs. untreated group.
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To evaluate effects of eicosanoid inhibitors during systemic infection, mice
were infected intravenously and treated with inhibitors by IP injection. After 6
days of daily administration of drugs, the mice were sacrificed on day 7 and
kidneys analyzed for fungal burden. After treatment with amphotericin B, lowest
fungal burden was observed.

Compared with control mice, treatment with

amphotericin B significantly reduced fungal burden in the kidney by
approximately 4 logs (Figure 27). Treatment with NDGA also reduced fungal
burden by approximately 2 logs.
indomethacin treatment.

However, we observed no effect with
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Figure 27. Effect of eicosanoid inhibitors or antifungal drugs on C. albicans
kidney burden during systemic infection. On day 0, the mice were challenged
by intravenous tail injection with C. albicans at the concentration of 2.5 x 105
CFU/mouse in 250 µl of sterile endotoxin-free PBS. From day 1 to day 6, mice
were daily administered drugs via intraperitoneal route at a concentration of 5
mg/kg for NDGA, indomethacin, and aspirin and 0.1 mg/kg for amphotericin B.
After 7 days post-inoculation, the mice were sacrificed, the kidneys excised,
homogenized and analyzed for fungal burden by serial dilution and plating onto
SD plates. Results are representative of three independent repeats. * P < 0.05
treated vs. untreated group.
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Analysis of PGE2 levels in serum samples revealed increased levels in
mice infected with C. albicans, compared with uninfected mice (Figure 28).
Treatment with NDGA and amphotericin B resulted in a reduction in PGE2 levels,
while indomethacin had little effect.

To determine the effect of eicosanoid

inhibitors on immune responses during systemic infection, the spleens were
harvested on day 7 following the daily drug treatment and cytokines were
analyzed in restimulated splenocyte cultures. Compared with uninfected animals,
there was a reduction in IFN-γ levels in infected mice (Figure 29). Treatment
with amphotericin B or NDGA restored IFN-γ production in splenocytes. A similar
trend was observed with pro-inflammatory cytokine TNF-.

Infected mice

showed induction of this cyotkine, which was further increased with amphotericin
B treatment.

Induction of the Th1 cytokine IL-12 was only observed in

amphotericin B treated animals, which correlates with reduced fungal burden.
Levels of IL-4 were extremely low, although levels correlated with fungal burden,
with lowest levels observed with ampB treatment. Overall this indicates that
infection is associated with reduced Th1 promoting cytokines (IFNγand IL-12)
and a reduction in fungal burden results in increased pro-inflammatory cytokines
(IFN-γ and TNF-).
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Figure 28. Effect of eicosanoid inhibitors or antifungal drugs on serum
PGE2 levels in mice systemically infected with C. albicans. On day 0, the
mice were challenged by intravenous tail injection with C. albicans at the
concentration of 2.5 x 105 CFU/mouse in 250 µl of sterile endotoxin-free PBS.
From day 1 to day 6, they were daily administered drugs via intraperitoneal route
at a concentration of 5 mg/kg for NDGA and indomethacin. For amphotericin B,
0.1 mg/kg/mice dose was used. On day 7, mice were sacrificed, their blood
collected in BD yellow vacutainer and spun at 1000xg. The serum was collected
to perform ELISA using monoclonal PGE2 kit. Results are representative of three
independent repeats. * P < 0.05 treated vs. untreated group. ** P < 0.05 treated
vs. untreated group.

138

**
**
*
*
Figure 29. Effect of eicosanoid inhibitors or antifungal drugs on splenic
cytokine levels in mice systemically infected with C. albicans. On day 0,
mice were challenged on day 1 via intravenous tail vein injection with C. albicans
at the concentration of 2.5 x 105 CFU/mouse in 250 µl of sterile endotoxin-free
PBS. From day 2 to day 6, they were daily administered drugs via intraperitoneal
route at a concentration of 5 mg/kg for NDGA and indomethacin. For
amphotericin B, 0.1 mg/kg/mice dose was used. On day 7, mice were sacrificed
and their spleens were excised and the splenocytes were isolated. C. albicans
were used at MOI 1:2 to stimulate the splenocytes. After 2 h of incubation, 2.5
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µg/ml of amphotericin B was added to prevent Candida overgrowth followed by
further incubation of 16 h at 37°C, 5% CO2 incubator. The supernatants were
collected and the levels of cytokines were measured by ELISA. Results are
representative of three independent repeats. * P < 0.05 treated vs. untreated
group.
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Figure 29 Continued
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DISCUSSION

PGE2 is a pleiotropic molecule that exerts various effects on immune
responses depending on the microenvironment, tissue, and cells involved [134,
In addition, PGE2 and fungal PGEx promote germination and biofilm

230].

formation by C. albicans [231, 232]. The ability to form hyphae is required for
virulence during systemic infection [13]. In addition, hyphal forms and ability to
germinate are associated with symptomatic vaginal infections [233, 234].
However, the role of PGE2 and other eicosanoids towards immunomodulation in
mucosal and systemic candidiasis is still largely unknown. In vitro, exposure to
eicosanoid inhibitors reduces fungal prostaglandin production, germination, and
biofilm formation [154, 157, 226, 231]. At higher doses, these drugs can exert
antifungal activity [152, 232, 235]. Therefore, we tested the ability of these drugs
to inhibit fungal growth during mucosal and systemic infections and investigate
effects on immune responses.
Vulvovaginal candidiasis (VVC) is a very common infection among
women.

C. albicans

is

the responsible causal organism in up to 80% of

vaginitis cases [236]. Studies have shown that unlike systemic infection caused
by C. albicans, vaginal infection is more associated with local immunity [74, 149,
237]. Recent studies have reported an increased levels of PGE2 from recurrent
VVC patients [150]. C. albicans has been shown to directly stimulate PGE2
production from vaginal epithelial cells [152].

In addition, exogenous PGE2

142
administration increases C. albicans vaginal infection levels during experimental
vaginitis [232]. However, the immunomodulatory effects of prostaglandins during
this local immune response are poorly understood [238].
Treatment with the non-specific LO/COX inhibitor NDGA locally during
experimental vaginitis dramatically reduced fungal burden. At similar doses,
NDGA was more effective than amphotericin B. However, a non-selective COX
inhibitor, indomethacin, had no effect, indicating that daily administration of drugs
is not having a non-specific effect on fungal colonization levels. At this point it is
unclear if the differences in the fungal burden is a consequence of hyphae versus
yeast numbers that could result in differences in cfu burden. Previous work by
Noverr et al demonstrated the effect of COX-inhibitors towards the inhibition of
Candida germination.

In both amphotericin B and NDGA treated mice, PGE2

levels were reduced compared with untreated mice. In the case of NDGA, this is
likely due to inhibition of host cell and/or fungal PGE2 production as previously
observed in vitro [154, 239, 240]. Interestingly, PGE2 production was elevated in
the indomethacin treated mice. This was unexpected; however, biphasic effects
of indomethacin on prostaglandin production have been reported, with low doses
promoting PGE2 production [241].

It is unknown what the local levels of

indomethacin are during vaginal treatment, but this may be one explanation for
these observations. Overall, fungal burden correlated with PGE2 levels. This
might be indicative of the fact that high concentrations of PGE2 are associated
with susceptibility towards developing vaginitis.
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Analysis of the associated local cytokines from the vaginal tissues showed
that infection resulted in reduced pro-inflammatory IFN-γ production. This has
also been observed clinically, with decreased IFN-γ associated with recurrent
vaginitis [242].

Treatment with either amphotericin B or NDGA resulted in

increased IFN- γ, which may be due to reduced fungal burden, or due to reduced
PGE2 levels, which can inhibit IFN- γ [243].

There was also reduced IL-10

production in infected mice, which has been reported previously in experimental
vaginitis [244]. IL-10 is an anti-inflammatory cytokine, which can inhibit activation
of innate effector cells, which mediate the symptoms of vaginitis. IL-10 levels
tend to correlate with fungal burden, as infection induces pro-inflammatory
responses [245]. Accordingly, Amphotericin B and NDGA treatment partially
rescued IL-10 production. While PGE2 is a known inducer of IL-10, we
hypothesize that the lack of fungal burden and antigenic stimulation is
responsible for reduced IL-10 production [246].

Overall, these results

emphasized the fact that increased levels of PGE2 are associated with increased
fungal burden and cytokines associated with local immune responses during
infection.
Systemic candidiasis is a clinically important infection and is associated
with high mortality rates [2, 3]. Both innate and adaptive immunity is required to
mount a protective response to infection. Treatment of mice with amphotericin B
reduced kidney fungal burden. In addition, treatment with NDGA also reduced C.
albicans levels. This was associated with a reduction in serum PGE2 levels.
Similar to the vaginal infection, overall C. albicans levels correlated with PGE2
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levels. Studies have shown the role of prostaglandins in generating nonprotective responses by dampening anti-fungal defenses [189]. We also
observed that treatment with amphotericin B and NDGA was associated with
elevated splenic IFN-γ and IL-12, which are required for generation of protective
Th1 responses during systemic infection [247]. High fungal burden in untreated
mice was associated with slightly increased IL-4 and low IL-12, indicative of a
non-protective Th2 response. This association of fungal burden with Th1 vs. Th2
responses has been demonstrated in previous work with mice having
disseminated candidiasis [74, 248]. Unlike like NDGA and amphotericin B,
indomethacin was not able to reduce the levels of PGE2 and the balance tilted
more towards non-protective response. This may be due to alternative effects of
indomethacin on the host immune response. For example, β-glucan, a fungal
cell

wall

component,

combined

with

indomethacin

can

result

in

immunocompromise leading to sepsis from the GI tract and mortality in mice
[249].

The lethality is strongly related to disruption of the cytokine network.

Similar results were observed with killed whole cells of C. albicans [250].
Therefore, different eicosanoid inhibitors may have unforeseen effects on global
inflammatory responses and must be tested in vivo to determine efficacy against
fungal infection.
Although our study points to the fact that PGE2 is one of the key
molecules involved in the process of exacerbating a progressive form of
disseminated candidiasis and aids in elevating Th2 responses, the underlying
mechanism for this process is not yet clear. From the previous studies showing
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the negative role played by the Th2 cytokines during disseminated candidiasis,
inhibition of PGE2 might prove beneficial for the host to clear-up the infection
[205, 251]. It is unclear whether NDGA works to inhibit C. albicans growth by
inhibiting PGE2 production, or whether direct effects of NDGA on fungal killing
resulting in reduced fungal burden causes a reduction in PGE2. Regardless, the
effect of this drug is beneficial and may exert synergistic effects on reducing
fungal levels in vivo in combination with a traditional antifungal.

Synergism

between amphotericin B and NDGA has already been observed in vitro [232].
This is extremely important as resistance to both polyene drugs (amphotericin B
drug class) and azoles are on the rise. New therapeutic strategies targeting both
PGE2 and fungal viability may be beneficial for treating fungal infections under
these kinds of circumstances.
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GENERAL CONCLUSION
Prostaglandins

are

pleiotropic

compounds

playing

an

array

of

immunomodulatory roles in the mammals. Depending on the type of interaction
and the receptors involved, they can have multiple effects on different cells types
at a very low (nanomolar) concentrations [134, 230].

Their roles have been

widely associated with the effector functions of many immune cells including
those of the innate immune system (macrophages, neutrophils), cells that bridge
innate and adaptive responses (dendritic cells, epithelial cells), and adaptive
immunity (T cells, B cells) [252].

They regulate both acute inflammatory

responses as well as chronic inflammation and memory immunity. PGE2
specifically influences phagocytosis and intracellular killing of microbial
pathogens as well as cytokine release from macrophages. PGE2 also regulates
release

of

effector

molecules,

migration,

maturation

and

secretion

of

immunomodulatory compounds from dendritic cells and lymphocytes [165, 167,
253-255].
The fact that C. albicans produces both endogenous PGE2-like
compounds as well as authentic PGE2 from host arachidonic acid suggests that
this fungal pathogen may directly influence host responses during colonization
and/or infection.

Production of eicosanoids by host cells can also be induced

upon interaction by fungal pathogens. C. albicans has been shown to be able to
induce the activation and transcription of host PGE2 production from various
immune cells such as macrophages, endothelial cells, and splenocytes [161,
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188, 189].

Therefore both fungal derived and host derived eicosanoids can

participate in driving immune responses during fungal infection. Our hypothesis
is that Production of oxylipins by both fungi and host modulate the host-pathogen
interaction in favor of non-resolving infection or persistence.

The goal of this

thesis was to determine the immunomodulatory roles of host and fungal
eicosanoids during interactions of C. albicans with the host.

For this purpose

we studied the role of prostaglandins in vitro (with dendritic cells and
macrophages) as well as in vivo using mucosal and systemic models.
From our studies with the effects of exogenous PGE2 on dendritic cellCandida interactions, the early cytokine analysis with both JAWSII cells and
primary pDCs and mDCs revealed upregulation of Th2 cytokines (IL-4) and
down-regulation of Th1 cytokines (IL-12) in the presence of hyphae. This is in
agreement with the previous data reporting a bias towards non-protective Th2
cytokine responses in macrophages and monocytes in the presence of hyphae,
but not yeast [80, 219, 220, 253-257]. However, the presence of PGE2 was
required for robust Th2 cytokine production from DCs in the presence of hyphae,
which is an activity previously reported for PGE2 [183]. Later cytokine analysis
also showed a shift towards a DC2 phenotype in primary DCs stimulated with
prostaglandins. The only significant difference in immune mediator production
that varied between yeast and hyphae pulsed cells was in host PGE2 production.
Hyphae stimulated significant production at 18 h, the time point used to harvest
DCs for adoptive transfer. This indicates that hyphae can prime DCs for PGE2
release, which could influence nearby immune cells.
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This difference in the pattern of PGE2 induction could be due to differential
PRR signaling. DCs recognize yeast and hyphal form of C. albicans via TL4 and
TLR2 receptors [80, 115, 116]. Also, studies have indicated that C. albicans
signaling via TLR2 pathway leads to the production of PGE2 from the host and
causes persistent type of infection [189].

Future studies in this area would

involve examining DC PGE2 production in the presence of yeast and hyphae in
PRR knockout mice. Overall, these data demonstrate that depending on the
morphotypes (yeast or hyphal form), the DCs have the ability to modulate the
immune responses in presence of exogenously added prostaglandins.
We observed evidence from early cytokine analysis that effects of
prostaglandin exposure are not limited to simply effects on Th1 and Th2
mediators. In addition, we demonstrated that pro-inflammatory cytokines IL-6
and IL-15 were upregulated in the hyphae/PGE2 group.

Early expression of

SOCS-3, a suppressor of cytokine, involved in promoting a DC2 phenotype was
also upregulated during this time point. [184]. This suggests that PGE2 exposure
can also stimulate pro-inflammatory mediators and that host cells counterregulate this with SOCS synthesis. In addition, the CD86 expression was greatly
increased in primary DCs pulsed with hyphae in the presence of PGE2, which
indicative of maturation and a heightened activation state.

Therefore, it was

unclear as to how these pulsed DCs would regulate subsequent adaptive
responses upon vaccination.
For DC vaccination, two rounds of priming were necessary to
induce robust responses. We showed that yeast pulsed pDCs imparts protection
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whereas mDCs are less protective in mice with systemic infection. This nonprotection was associated with splenic and kidney Th2 responses and at later
stages, exacerbated local Th17 responses accompanied by uncontrolled fungal
growth at the site of infection. Another major difference between the responses
to mDCs and pDCs was evident in the kidney Th17 cytokines. Although we
observed slight protection with double adoptive transfer with mDCs pulsed with
yeast, there was dramatic IL-17 and IL-23 cytokine staining in the kidneys. The
ability of mDCs to promote Th17 responses compared with pDCs has been
reported previously [79]. Therefore, mDCs may not be appropriate for fungal
vaccination strategies and these results underscore the importance and
variability of DC subsets.
Our results are in alignment with other studies indicating that both IL-23
and IL-17 can inhibit neutrophil antifungal activity resulting in pathological form of
inflammation associated with impaired antifungal resistance [79]. Therefore,
although neutrophils were recruited to the kidneys, the antifungal activity is likely
diminished, as indicated by the high fungal burden. To investigate this concept
further, it would be necessary to isolate kidney or bloodstream PMNs and
examine antifungal activity in vitro. While the Th17 response is required to
defend against mucosal and acute systemic infections, ours is the first study to
report presence of Th17 cytokines in the mice kidneys of vaccinated mice during
systemic candidiasis and its associated lack of protection. This indicates that IL17 helps initiate protective innate responses during C. albicans infections, but if
left unchecked, may exacerbate immunopathological inflammation.

Future
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studies examining the role of Th17 responses during afferent vs. efferent
responses are necessary to investigate this possibility.
We examined the effect of PGE2 and PGEx during the interaction of C.
albicans with the macrophage cell line, RAW264.7. In this case, we used PGEx
derived from arachidonic acid, which is 99.9% PGE2.

Both the fungal derived

and commercially available prostaglandins inhibited phagocytosis of C. albicans,
while increasing intracellular survival in activated macrophages. Interestingly,
these effects were more dramatic with PGEx, compared with PGE2.

These

experiments confirmed that host PGE2 and fungal PGEx aid in overcoming
antifungal defenses of macrophages.

The fact that PGEx produced a more

potent response may be due to effects of the endogenous PGE2 cross-reactive
compound that is co-isolated with fungal PGE2. However, we did not observe
such dramatic differences in responses to PGEx vs. PGE2 with dendritic cells in
terms of promoting non-protective responses. To investigate the variable effects
of specifically endogenous PGEx on host cells, it would be necessary to isolate
the compound in enough quantity to perform experiments. Without addition of
exogenous arachidonic acid, very small quantities of PGEx are produced.
Therefore, these experiments would be difficult to perform.
We have made some advancement in our understanding on how C.
albicans interacts with RAW264.7 cells in presence of prostaglandins, but large
gaps in our knowledge still remains to verify the underlying mechanism. Both
reactive oxygen and nitrogen species (ROI/RNI) production contribute to the
candidicidal activity of macrophages, with nitric oxide and peroxynitrite exhibiting
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the strongest antifungal activity. Our data indicate that a nitric oxide synthase
inhibitor slightly reduced NO production from macrophages, which resulted in
increased fungal burden in control and PGE2 treated groups.

However, with

PGEx treated groups, we observed no increase in fungal burden in the presence
of the inhibitor. This may be due to the fact that fungal burden was already
maximal with PGE2 treatment. However, neither PGE2 nor PGEx alone inhibited
nitric oxide or peroxynitrite production; therefore, this is not the mechanism of
action of these compounds.
Future studies should be directed at examining non-oxidative mechanisms
that mediate intracellular killing of C. albicans.

While investigators have

demonstrated that C. albicans traffics to the phagolysosome, there may be some
variation in microenvironment within this compartment that impacts killing [216].
For example, it was recently shown that there is inhibition of the C. albicans
phagosome fusing with compartments enriched in the lysobisphosphatidic acid
[258]. In comparing a wildtype and hyphal deficient mutant, the wildtype strain
displayed additional specific survival strategies to prevent its targeting to
compartments displaying late endosomal/lysosomal features, such as induction
of active recycling out of phagosomes of the lysosomal membrane protein LAMP1, the lysosomal protease cathepsin D at later time points. Detailed microscopic
and cell trafficking experiments are needed to further examine the effects of
prostaglandins in the intracellular fate of C. albicans.
For synthesis of prostaglandins from arachidonic acid precursors, two
cyclooxygenase (COX) enzymes, COX-1 and COX-2, are involved. COX-1 is
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expressed constitutively and is responsible for steady-state eicosanoid
production whereas COX-2 is the inducible form and responsible for
inflammatory eicosanoid production [230]. Previous studies have demonstrated
that C. albicans induces PGE2 production via COX-2 in vitro [161]. This enzyme
can be inhibited by treatment with various nonsteroidal anti-inflammatory drugs
(NSAIDS) including aspirin, indomethacin, naproxen, etc. In addition, certain
plant polyphenols inhibit COX activity, including resveratrol and NDGA, which
also inhibits lipoxygenase.

We evaluated the effects of eicosanoid inhibitors

(both an NSAID and plant polyphenol) to determine the effects of host
eicosanoids in vivo in mucosal and systemic infection models. It was important
to test several infection models as immune responses to C. albicans infections
are distinct depending on the tissue.
C. albicans vaginitis is a superficial mucosal infection that does not follow
the normal paradigm of protective immunity [259]. While cell-mediated immunity
is considered the predominant host defense mechanism against other mucosal
candidal infections, studies have revealed a lack of a protective role for adaptive
immunity. Instead aberrant innate responses to C. albicans colonization are
responsible, mediated by epithelial cells and neutrophils [260].

In terms of

control of the aberrant response, it is believed that immunoregulatory activities of
local dendritic cells participate in promoting tolerance to the colonization state. In
the experimental vaginitis model, upon treatment with NDGA and indomethacin,
our studies demonstrated decreased fungal burden and PGE2 levels. Treatment
with either NDGA resulted in increased IFN-γ, which may be due to reduced
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fungal burden, or due to reduced PGE2 levels, which can inhibit IFN- [243].
NDGA treatment also partially restored IL-10 production.

IL-10 is an anti-

inflammatory cytokine, which can inhibit activation of innate effector cells, which
mediate the symptoms of vaginitis. IL-10 levels tend to correlate with reduced
fungal burden, as infection induces pro-inflammatory responses [244]. While
PGE2 is a known inducer of IL-10, we hypothesize that the lack of fungal burden
and antigenic stimulation is responsible for reduced IL-10 production [246].
Overall, these results emphasized the fact that increased levels of PGE2 are
associated with increased fungal burden and cytokines associated with local
immune responses during infection.
Future studies focused on the role of PGE2 in vaginitis could also be
examine the growth state of C. albicans in the vaginal tract as PGE2 also
enhances morphogenesis and biofilm formation. Recently, it was reported that
C. albicans forms biofilms on the vaginal mucosa. However, the role of biofilms
in pathogenesis during vaginitis is unknown [261, 262]. In line with this, the role
of estrogen in this model should be investigated, which is required for a robust
vaginal infection.

Estrogen has direct effects on inducing C. albicans

morphogenesis [263]. PGE2 stimulates expression and activity of aromatase, the
enzyme that is responsible for a key step in the biosynthesis of estrogens [264].
This results in local production of estrogen, which induces PGE2 formation and
establishes a positive feedback cycle. Therefore, effects on both the fungus and
host may work together to promote vaginal fungal growth and infection.
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We also investigated effects of eicosanoid inhibitors during systemic
candidiasis. The ability to clear or control a systemic infection with Candida is
dependent on the elaboration of a protective adaptive immune response,
characterized by induction of Th1 cells and production of pro-inflammatory
cytokines. A non-protective response is characterized by expansion of Th2 cells
and production of Th2 cytokines [222]. Treatment of mice with NDGA reduced C.
albicans level in the kidney, which was associated with a reduction in serum
PGE2 levels. We also observed that treatment with NDGA was associated with
elevated splenic IFN-γ and IL-12, which are required for generation of protective
Th1 responses during systemic infection [247]. Unlike like NDGA, indomethacin
was not able to reduce the levels of PGE2 and the balance tilted more towards
non-protective response. While this may be due to alternative effects of
indomethacin in protective inflammatory responses, this may also be due to
ineffectiveness at directly killing C. albicans or inhibiting fungal prostaglandin
production during infection.

Pharmacologically, this drug may not access C.

albicans at the site of infection or may lose efficacy in vivo.

There is the

possibility that using nanotechnology or lipid-based delivery systems may be
more effective. Overall, these studies suggested that manipulation of eicosanoid
production are effective at reducing fungal burden without suppressing
inflammatory response and inhibit fungal growth at same time.
Although the work presented in this dissertation has provided an
insight on the immunomodulatory role of prostaglandins during Candida-host
interactions, many questions still require further investigation.

It would be
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important to test responses to C. albicans mutants lacking the ability to produce
eicosanoids would be affected. For this purpose, all the genes responsible for
production of eicosanoids in C. albicans need to be identified and mutants have
to be made to study the downstream response when interacting with the host
cells.

However, the enzymes and metabolic pathways of fungal eicosanoid

production are mostly unknown.

This is due largely to differences between

fungal and mammalian enzymes at both the nucleic and amino acid sequence
level. So far, OLE2 (fatty acid desaturase) and FET3 (multicopper oxidase) has
been associated with decreased PGE2 production but they did not completely
abrogate it [154]. In addition, a bifunctional LTA4 hydrolase was cloned and
characterized from S. cerevisiae [265]. This enzyme possessed 42% identity
with mammalian leukotriene A4 (LTA4) hydrolase and produced LTB4 from LTA4
in vitro [266]. There exists a homolog of LTA4 hydrolase in C. albicans, which
can produce LTB4 in vitro. Therefore, future studies could focus on effects of
fungal leukotrienes during infection, which may exert completely different effects
on the host response compared with prostaglandins.
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Candida albicans, an opportunistic fungal pathogen, poses a significant
clinical threat to immunocompromised patients. Diseases associated with this
fungus ranges from superficial mucosal infection to life-threatening systemic
candidiasis. The mechanisms by which Candida persists at mucosal surfaces in
the

face

of

an

adaptive

response

are

unclear.

Candida

produces

immunomodulatory oxylipins that cross-react functionally with host eicosanoids,
which are considered to play important role in regulating innate and adaptive
immune responses. Our objective was to characterize the role of prostaglandins
produced by the host and this fungus during host pathogen interactions, both in
vitro with dendritic cells (DCs) and macrophages, and in vivo during
pathogenesis. At early time point, there was upregulation of Th2 cytokines IL-4,
IL-10, and IL-13 by both plasmacytoid and myeloid DCs in the presence of
hyphae and PGE2. At later time points, fungal or host PGE2 treatment resulted in
decreased Th1 cytokine production (IL-12 and IL-6) and slightly increased Th2

191
cytokine production (IL-4). DC vaccination experiments demonstrated that yeast
pulsed DCs imparted protection, which was abrogated with exposure to host or
fungal PGE2.

Non-protective responses were associated with Th2 cytokine

production, and at later stages, exacerbated Th17 responses accompanied by
uncontrolled fungal growth. Ours is the first study to report presence of Th17
cytokines in the mice kidneys during systemic candidiasis and its associated lack
of protection. We also demonstrated that during the interaction of C. albicans
with the macrophages, PGE2 and PGEx decreased phagocytosis and increased
intracellular survival. We also investigated the effects of eicosanoid inhibitors
during mucosal and systemic infection models. During experimental C. albicans
vaginitis, treatment with inhibitors locally resulted in decreased fungal burden and
PGE2 levels.

Similar results were observed during systemic infection, which

correlated with restoration of Th1 cytokines.

These studies suggested that

balanced manipulation with eicosanoid production can work without suppressing
inflammatory response and inhibit fungal growth at same time. This could provide
newer avenues for developing novel pharmacological intervention strategies to
treat C. albicans infections.
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